var title_f35_24_36224="Ictal SPECT scan";
var content_f35_24_36224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Ictal spect hyperperfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An ictal SPECT scan showing hyperperfusion at a likely seizure focus in the left temporal region (see boxed area).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure courtesy of Hiba Arif, MD and Lawrence J Hirsch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36224=[""].join("\n");
var outline_f35_24_36224=null;
var title_f35_24_36225="Lateral ligament of the rectum";
var content_f35_24_36225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Lateral ligament of the rectum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 486px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts&nbsp;a lateral ligament of the rectum, which is comprised of the fascia propria. Typically, this is an avascular structure, but can contain small arterial and venous vessels.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36225=[""].join("\n");
var outline_f35_24_36225=null;
var title_f35_24_36226="Patient information: Hypertrophic cardiomyopathy in children (The Basics)";
var content_f35_24_36226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83800\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/46/14053\">",
"         Heart with hypertrophic cardiomyopathy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/28/35266\">",
"         Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/5/36946\">",
"         Patient information: Syncope (fainting) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/20/11589\">",
"         Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hypertrophic cardiomyopathy in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hypertrophic-cardiomyopathy-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9604124\">",
"      <span class=\"h1\">",
"       What is hypertrophic cardiomyopathy in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy in children is a condition that makes the heart muscle get too bulky (",
"      <a class=\"graphic graphic_figure graphicRef50899 \" href=\"mobipreview.htm?13/46/14053\">",
"       figure 1",
"      </a>",
"      ). When this happens, it can keep the heart from pumping blood as well as it should. This can cause breathing problems, chest pain, and other symptoms.",
"     </p>",
"     <p>",
"      Hypertrophic cardiomyopathy is usually caused by an abnormal gene that runs in families. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604139\">",
"      <span class=\"h1\">",
"       What are the symptoms of hypertrophic cardiomyopathy in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most children have no symptoms. A doctor or nurse might find hypertrophic cardiomyopathy during a routine exam, such as before a child starts playing sports.",
"     </p>",
"     <p>",
"      When symptoms do happen, they can start in childhood or the teenage years. Symptoms are most common around puberty. Puberty is a term for the changes in the body that happen during the pre-teen and teen years. The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breathing problems, especially during exercise",
"       </li>",
"       <li>",
"        Chest pain that is often worse during exercise",
"       </li>",
"       <li>",
"        Fainting or feeling about to faint",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604154\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child has symptoms of hypertrophic cardiomyopathy, especially during exercise, call your doctor or nurse right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604169\">",
"      <span class=\"h1\">",
"       Is there a test for hypertrophic cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If the doctor or nurse thinks your child might have hypertrophic cardiomyopathy, he or she can order tests. These can include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An &ldquo;electrocardiogram&rdquo; (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;) &ndash; This test measures electrical activity in the heart. It can show if the heart is beating in a normal pattern and rhythm. The doctor might have your child exercise during the test.",
"       </li>",
"       <li>",
"        An &ldquo;echocardiogram&rdquo; (also called &ldquo;echo&rdquo;) &ndash; This test uses sound waves to create an image of the heart. Doctors use it to see how thick the walls of the heart are, measure the spaces inside the heart, and see how well the heart pumps blood. The doctor might have your child exercise during the test or right beforehand.",
"       </li>",
"       <li>",
"        A Holter monitor &ndash; This is a small, portable machine your child wears. It records the heart&rsquo;s electrical activity over 1 or 2 days. It can show heart rhythm problems that can be dangerous.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on your child&rsquo;s situation, he or she might need other tests, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cardiac catheterization (also called &ldquo;cardiac cath&rdquo; or &ldquo;coronary angiography&rdquo;)&nbsp;&mdash; During this test, the doctor places a thin plastic tube in a blood vessel in your child&rsquo;s leg and moves the tube up to the heart. The doctor can also put dye into the heart through the tube. This test can help measure pressure inside the heart and find problems caused by hypertrophic cardiomyopathy.",
"       </li>",
"       <li>",
"        Cardiac MRI",
"        <strong>",
"         &ndash;",
"        </strong>",
"        This test creates images of the heart. It can show parts of the heart that are hard to see with an echocardiogram and give doctors other information about the heart.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child has a parent, brother, or sister with hypertrophic cardiomyopathy, the doctor might suggest your child get tested for it. He or she might need tests every year between the ages of 12 and 20. People older than 20 do not need tests as often.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604186\">",
"      <span class=\"h1\">",
"       How is hypertrophic cardiomyopathy in children treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your child does not have symptoms, he or she probably will not need treatment. If symptoms happen, treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to help with chest pain or breathing problems",
"       </li>",
"       <li>",
"        Medicines to control the heart&rsquo;s rhythm",
"       </li>",
"       <li>",
"        A device called a &ldquo;defibrillator&rdquo; &ndash; This can sense and control abnormal heartbeats. It is placed under the skin near the heart.",
"       </li>",
"       <li>",
"        Surgery &ndash; Doctors can do surgery to remove parts of the heart muscle. But this is done only when medicines do not work.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604201\">",
"      <span class=\"h1\">",
"       Can I do anything to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It is important to ask your child&rsquo;s doctor what types of physical activity are safe for your child. Children with hypertrophic cardiomyopathy can have problems that make exercise dangerous or even life-threatening. Your child might need to avoid certain sports or activities.",
"     </p>",
"     <p>",
"      You can also make sure your child always drinks enough water. People with hypertrophic cardiomyopathy sometimes have problems, such as fainting, when they do not get enough fluids. On the other hand, some people with hypertrophic cardiomyopathy need to be careful if they have too much salt and water. Ask your doctor what is safe for your child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604218\">",
"      <span class=\"h1\">",
"       What will my child&rsquo;s life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A few people with hypertrophic cardiomyopathy get serious heart problems, but most people can live normal lives. Your child might need regular exams and tests, medicines, or other treatments. He or she might need to avoid certain foods or activities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9604235\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/28/35266?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/5/36946?source=see_link\">",
"       Patient information: Syncope (fainting) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/24/36226?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83800 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36226=[""].join("\n");
var outline_f35_24_36226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604124\">",
"      What is hypertrophic cardiomyopathy in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604139\">",
"      What are the symptoms of hypertrophic cardiomyopathy in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604154\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604169\">",
"      Is there a test for hypertrophic cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604186\">",
"      How is hypertrophic cardiomyopathy in children treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604201\">",
"      Can I do anything to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604218\">",
"      What will my child&rsquo;s life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9604235\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/46/14053\">",
"      Heart with hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/5/36946?source=related_link\">",
"      Patient information: Syncope (fainting) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36227="Gadofosveset: Patient drug information";
var content_f35_24_36227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Gadofosveset: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/49/29461?source=see_link\">",
"     see \"Gadofosveset: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10117338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ablavar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, this drug may cause a very bad health problem. Call your doctor right away if you have joint stiffness, muscle weakness, very bad bone pain in the hips or ribs, yellow eyes, or very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during an MRA (magnetic resonance angiography) test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702181",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to gadofosveset or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698968",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone pain in the hips or ribs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11953 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36227=[""].join("\n");
var outline_f35_24_36227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10117338\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029155\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029157\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029156\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029160\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029161\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029163\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029159\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029165\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/49/29461?source=related_link\">",
"      Gadofosveset: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36228="Atrial flutter: Epidemiology, classification, and risk factors";
var content_f35_24_36228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Atrial flutter: Epidemiology, classification, and risk factors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36228/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36228/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36228/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36228/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36228/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36228/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/24/36228/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter occurs in many of the same situations as atrial fibrillation, which is much more common. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .) Atrial flutter may be a stable rhythm or a bridge arrhythmia between sinus rhythm and atrial fibrillation. It may also be associated with a variety of other supraventricular arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite much information about the mechanisms for atrial flutter and effective therapies for its cure, little is known about its epidemiology. Many clinical trials have included patients with atrial flutter as well as atrial fibrillation or both arrhythmias in the same patient.",
"   </p>",
"   <p>",
"    Much of the information about atrial flutter has been derived from patients referred to tertiary care centers; as a result, the incidence of atrial flutter in the general population has been uncertain. This issue was addressed in a large database of 58,820 residents who obtained their care from one major medical center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1\">",
"     1",
"    </a>",
"    ]. The overall incidence of new cases of atrial flutter during a four year period was 88 per 100,000 person-years, ranging from 5 to 587 per 100,000 in those less than 50 and more than 80 years of age, respectively. Atrial flutter was 2.5 times more common in men. Based upon these data, it was estimated that the incidence of atrial flutter in the United States is 200,000 new cases per year.",
"   </p>",
"   <p>",
"    The incidence of this arrhythmia, as with atrial fibrillation, is greatest when underlying heart disease is associated with left atrial enlargement, or left ventricular or biventricular failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In the population-based study noted above, the risk of developing atrial flutter increased 3.5 times in patients with heart failure and 1.9 times in those with chronic obstructive lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, when the patient who has experienced atrial flutter is in sinus rhythm, there is often evidence of atrial disease as manifested by abnormal P waves with findings suggestive of an intra-atrial conduction defect or left atrial enlargement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional classification distinguishes two types of atrial flutter: type I and type II (",
"    <a class=\"graphic graphic_waveform graphicRef74395 \" href=\"mobipreview.htm?37/54/38757\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef68846 \" href=\"mobipreview.htm?23/35/24119\">",
"     waveform 2",
"    </a>",
"    ). These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter, particularly type II atrial flutter, is unusual in the normal heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. In the population-based study discussed above, atrial flutter without an identifiable predisposing factor (\"lone atrial flutter\") occurred in only 3 of 181 patients (1.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1\">",
"     1",
"    </a>",
"    ]. In comparison, the rate of lone atrial flutter was 8 percent in a series of 380 children and young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial flutter is most often seen in left ventricular dysfunction, rheumatic heart disease (particularly if the mitral valve is involved), unoperated and repaired congenital heart disease, and after cardiac surgery even when atriotomy is not part of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/2,3,6\">",
"     2,3,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H2#H2\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Little is known about the relationship between inflammation and atrial flutter. The appearance of inducible atrial flutter in a canine sterile pericarditis model, however, and its prevention with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    suggests that inflammation can be an etiologic factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/7\">",
"     7",
"    </a>",
"    ]. Spontaneous atrial fibrillation has been associated with elevated C-reactive protein levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/8\">",
"     8",
"    </a>",
"    ], but, to the author's knowledge, a similar association has not been reported for atrial flutter.",
"   </p>",
"   <p>",
"    Atrial flutter, however, may beget inflammation. A prospective study of the levels of C-reactive protein and interleukin-6 obtained before and after curative ablation for atrial flutter found that peripheral levels of these biomarkers were high prior to ablation and fell after ablation, suggesting that atrial flutter was the cause and not the effect of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other underlying conditions can predispose to the development of atrial flutter. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any of the disorders that can cause atrial fibrillation, including thyrotoxicosis, obesity, the sick sinus syndrome, pericarditis, pulmonary disease, and pulmonary embolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"       \"Epidemiology of and risk factors for atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mitral valve prolapse, which may be associated with altered refractoriness in the atria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17719?source=see_link\">",
"       \"Arrhythmic complications of mitral valve prolapse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial flutter is a relatively uncommon complication of an acute myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/11,12\">",
"       11,12",
"      </a>",
"      ] and is rarely, if ever, a manifestation of digitalis toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=see_link\">",
"       \"Supraventricular arrhythmias after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=see_link\">",
"       \"Basic approach to arrhythmias due to digoxin toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Atrial flutter can occur after cardiac surgery, both as a postoperative complication and as a late arrhythmia. The atrial flutter in these patients is re-entrant and may involve atypical isthmuses between natural barriers, atrial incisions, and scar as well as the cavotricuspid isthmus, the site of involvement in typical type I atrial flutter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link&amp;anchor=H2#H2\">",
"       \"Atrial fibrillation and flutter after cardiac surgery\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients develop atypical (type II) left atrial flutter after pulmonary vein isolation for AF. These arrhythmias may be due to circuits created by scar from LA ablations, but are often amenable to ablation themselves. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40938?source=see_link&amp;anchor=H26#H26\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Left atrial flutter'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The distribution of causes varies with age. In the population-based study that primarily consisted of adults, there were 181 new cases of atrial flutter: 60 percent occurred within 30 days of a probable predisposing event (eg, cardiac surgery in 23 percent, pneumonia), 16 percent were attributable to heart failure and 12 percent to chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1\">",
"     1",
"    </a>",
"    ]. In comparison, in the report of 380 children and young adults, 81 percent had congenital heart disease (60 percent repaired, 13 percent palliated, and 8 percent unoperated), 6 percent had cardiomyopathy, 4 percent rheumatic heart disease, and 2 percent other lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the etiology, the autonomic nervous system may play a role in the initiation of atrial flutter, similar to its role in initiating atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link&amp;anchor=H5#H5\">",
"     \"Paroxysmal atrial fibrillation\", section on 'Autonomic dysfunction'",
"    </a>",
"    .) This was illustrated in a study that analyzed the changes in heart rate variability in 12 patients with paroxysmal type I atrial flutter; there was a shift in sympathovagal balance, with an increase in sympathetic activity and vagal withdrawal, beginning six minutes before arrhythmia onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36228/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/16/8451?source=see_link\">",
"       \"Patient information: Atrial flutter (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21096878\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial flutter (AFl) is less common than atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AFl is associated with left atrial enlargement, or left ventricular or biventricular dysfunction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two types of AFl have been identified (types I and II), which differ based on their electrophysiologic properties. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AFl, particularly type II, is unusual in the normal heart. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AFl is commonly seen in the following cardiac conditions: rheumatic heart disease (particularly if the mitral valve is involved), unoperated and repaired congenital heart disease, and after cardiac surgery even when atriotomy is not part of the procedure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/1\">",
"      Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:2242.",
"     </a>",
"    </li>",
"    <li>",
"     Friedberg CK. Diseases of the Heart, Saunders, Philadelphia 1966.",
"    </li>",
"    <li>",
"     Lewis T. Diseases of the Heart, MacMillan, London 1948.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/4\">",
"      Leier CV, Meacham JA, Schaal SF. Prolonged atrial conduction. A major predisposing factor for the development of atrial flutter. Circulation 1978; 57:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/5\">",
"      FOSMOE RJ, AVERILL KH, LAMB LE. Electrocardiographic findings in 67,375 asymptomatic subjects. II. Supraventricular arrhythmias. Am J Cardiol 1960; 6:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/6\">",
"      Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol 1985; 6:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/7\">",
"      Goldstein RN, Ryu K, Khrestian C, et al. Prednisone prevents inducible atrial flutter in the canine sterile pericarditis model. J Cardiovasc Electrophysiol 2008; 19:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/8\">",
"      Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004; 25:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/9\">",
"      Marcus GM, Smith LM, Glidden DV, et al. Markers of inflammation before and after curative ablation of atrial flutter. Heart Rhythm 2008; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/10\">",
"      Dobmeyer DJ, Stine RA, Leier CV, Schaal SF. Electrophysiologic mechanisms of provoked atrial flutter in mitral valve prolapse syndrome. Am J Cardiol 1985; 56:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/11\">",
"      JULIAN DG, VALENTINE PA, MILLER GG. DISTURBANCES OF RATE, RHYTHM AND CONDUCTION IN ACUTE MYOCARDIAL INFARCTION: A PROSPECTIVE STUDY OF 100 CONSECUTIVE UNSELECTED PATIENTS WITH THE AID OF ELECTROCARDIOGRAPHIC MONITORING. Am J Med 1964; 37:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/12\">",
"      Meltzer, LE, Kitchell, JB. The incidence of arrhythmias associated with acute myocardial infarction. Prog Cardiovasc Dis 1966; 9:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/13\">",
"      DELMAN AJ, STEIN E. ATRIAL FLUTTER SECONDARY TO DIGITALIS TOXICITY. REPORT OF THREE CASES AND REVIEW OF THE LITERATURE. Circulation 1964; 29:SUPPL:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/14\">",
"      FRIEDBERG CK, DONOSO E. Arrhythmias and conduction disturbances due to digitalis. Prog Cardiovasc Dis 1960; 2:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36228/abstract/15\">",
"      Wen ZC, Chen SA, Tai CT, et al. Role of autonomic tone in facilitating spontaneous onset of typical atrial flutter. J Am Coll Cardiol 1998; 31:602.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1056 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36228=[""].join("\n");
var outline_f35_24_36228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21096878\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21096878\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1056|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?37/54/38757\" title=\"waveform 1\">",
"      Typical atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?23/35/24119\" title=\"waveform 2\">",
"      Atrial flutter Type II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/19/17719?source=related_link\">",
"      Arrhythmic complications of mitral valve prolapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/16/8451?source=related_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/14/16615?source=related_link\">",
"      Supraventricular arrhythmias after myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36229="Cutaneous larva migrans (creeping eruption)";
var content_f35_24_36229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cutaneous larva migrans (creeping eruption)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36229/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/24/36229/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous larva migrans (CLM) refers to human infection with hookworms that are not natural human parasites. CLM frequently occurs as a result of human infection with the larvae of the dog or cat hookworm, Ancylostoma braziliense or Ancylostoma caninum; it may also be caused by other animal hookworms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/1\">",
"     1",
"    </a>",
"    ]. The terms cutaneous larva migrans and &lsquo;creeping eruption&rsquo; refer to intradermal migration of nonhuman larvae which may manifest as a linear or serpiginous cutaneous track [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31956589\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hookworms responsible for cutaneous larva migrans (CLM) are distributed worldwide; infection is more frequent in warmer climates, especially in the tropical and subtropical countries of Southeast Asia, Africa, South America, Caribbean, and the southeastern parts of the United States. Larvae are found on sandy beaches, in sand boxes, and under dwellings.",
"   </p>",
"   <p>",
"    Individuals at greatest risk include travelers, children, swimmers and laborers whose activities bring their skin in contact with contaminated soil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Cutaneous larva migrans is a common cause of dermatologic disease among those returning from travel in tropical regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. In one series of British travelers, infections were acquired most commonly in Africa, the Caribbean, Southeast Asia, and, less commonly, Central and South America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=see_link\">",
"     \"Skin lesions in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31956718\">",
"    <span class=\"h2\">",
"     Life cycle",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hookworm life cycle in the definitive host is very similar to the hookworm life cycle for human species (",
"    <a class=\"graphic graphic_figure graphicRef61675 \" href=\"mobipreview.htm?8/7/8310\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73772 \" href=\"mobipreview.htm?2/14/2279\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42437?source=see_link\">",
"     \"Hookworm infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eggs are passed in the stool of the definitive host (adult dog or cat). Under favorable conditions (moisture, warmth, shade), rhabditiform larvae hatch in one to two days.&nbsp;After 5 to 10 days (and two molts), they become filariform (third-stage) larvae, which are infective and can survive three to four weeks in favorable environmental conditions.&nbsp;",
"   </p>",
"   <p>",
"    Upon contact with the non-human animal host, the filariform larvae penetrate the skin and are carried through the blood vessels to the lungs, where they penetrate into the pulmonary alveoli, ascend the bronchial tree to the pharynx, and are swallowed.&nbsp;The larvae reach the small intestine, where they reside and mature into adults, which attach to the intestinal wall.&nbsp;Some larvae become arrested in the tissues, and serve as source of infection for puppies or kittens via transmammary (and possibly transplacental) routes.",
"   </p>",
"   <p>",
"    Humans may become infected when filariform larvae in the soil partially penetrate the skin. The larvae of most species cannot mature within the human host. They migrate within the epidermis and produce an inflammatory reaction along the cutaneous tract of their migration, which may continue for weeks. Some larvae may persist in deeper tissue. Rarely, pulmonary involvement can also occur, either via direct invasion or secondary to a systemic immunologic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CUTANEOUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous larva migrans (CLM) occurs most frequently on the lower extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. In a report of 98 travelers, lesions most often involved the lower extremities (73 percent); the buttocks and anogenital region, trunk, and upper extremities were involved in 13, 7, and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initially a pruritic erythematous papule can develop at the site of each larval penetration (although many patients are unaware of the penetration site). With exposure to heavily contaminated soil, up to several hundred pruritic papules may develop. Within two to three days thereafter, intensely pruritic, elevated, serpiginous, reddish-brown lesions appear as the larvae migrate at a rate of several millimeters per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/15\">",
"     15",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef60144 \" href=\"mobipreview.htm?39/63/40944\">",
"     picture 1",
"    </a>",
"    ). At times the onset of these serpiginous lesions may be delayed for months after exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Vesiculobullous lesions develop in about 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/16\">",
"     16",
"    </a>",
"    ], and nodular and bullous lesions may delay the diagnostic recognition of their etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/19\">",
"     19",
"    </a>",
"    ]. Lesions may become vesiculated, encrusted, or secondarily infected. The pruritus can be so intense that it causes sleep disturbance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/16,20\">",
"     16,20",
"    </a>",
"    ]. Eventually the lesions resolve spontaneously in two to eight weeks in the absence of specific therapy, although longer periods of infection have occasionally been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, cutaneous symptoms may recur days to months later. In one series, 29 percent of patients had lesions that persisted for one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/14\">",
"     14",
"    </a>",
"    ]. Occasionally larvae persist in follicles and cause disease for as long as two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hookworm folliculitis is an uncommon form of CLM that consists of numerous follicular, erythematous, and pruritic papules and pustules. Serpiginous tracks may be absent or relatively short [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cutaneous larva migrans is based on clinical history and physical findings. Infected patients typically have a history of exposure to contaminated soil or sand (walking barefoot or lying on sand) and the characteristic serpiginous lesion on the skin (",
"    <a class=\"graphic graphic_picture graphicRef60144 \" href=\"mobipreview.htm?39/63/40944\">",
"     picture 1",
"    </a>",
"    ). Eosinophilia is relatively rare.",
"   </p>",
"   <p>",
"    The principal differential diagnosis is the larva currens (\"running\" larva) of strongyloidiasis. Larva currens is notable for its rapidity (the larval track can progresses approximately 1 cm in five minutes), compared to CLM (where the larval track can progress approximately 1 cm per hour). The conditions usually can be distinguished clinically because CLM lesions advance at a rate of up to 1 to 2 cm per day, whereas larva currens lesions progress more rapidly (up to 5 to 15",
"    <span class=\"nowrap\">",
"     cm/hour).",
"    </span>",
"    Other migrating nematode infections due to gnathostomiasis and loiasis cause subcutaneous migratory swellings, not dermal lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11193?source=see_link\">",
"     \"Strongyloidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44168?source=see_link\">",
"     \"Miscellaneous nematodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36263?source=see_link\">",
"     \"Loiasis (Loa loa infection)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=see_link\">",
"     \"Skin lesions in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthelminthic therapy for cutaneous larva migrans is helpful for relieving symptoms and reducing the likelihood of bacterial superinfection.",
"   </p>",
"   <p>",
"    Options for treatment include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    . The preferred treatment is ivermectin (200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    orally once daily for one or two days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Alternatively, albendazole may be used (400 mg orally for three days). For patients with extensive or multiple lesions, a seven day course of albendazole may be administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/29\">",
"     29",
"    </a>",
"    ]. Symptoms generally disappear within one week after treatment; frequently the pruritus settles before the dermatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Topical agents are an alternative treatment option though they can be difficult to obtain. Topical thiabendazole (15 percent in a hygroscopic base for five days) is effective in alleviating pruritus and halting progression of lesions, usually within two days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/14,27\">",
"     14,27",
"    </a>",
"    ]. A topical 10 percent albendazole ointment, prepared by crushing three 400 mg tablets of albendazole in 12 g of petroleum jelly, has also been reported to be effective when administered three times daily for 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to antiparasitic agents, antihistamines are helpful for management of pruritus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous dissemination of larvae to the lungs is relatively rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/13\">",
"     13",
"    </a>",
"    ]. The most frequent manifestation is dry cough that starts about one week after cutaneous penetration. The cough usually lasts for one to two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/31\">",
"     31",
"    </a>",
"    ] but may rarely persist for up to nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A presumptive diagnosis of pulmonary involvement in cutaneous larva migrans is made when respiratory symptoms develop in the presence of the typical cutaneous lesions. Further diagnostic evaluation is not usually necessary.",
"   </p>",
"   <p>",
"    Chest radiography may demonstrate transient migratory infiltrates (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81742 \" href=\"mobipreview.htm?32/39/33393\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36229/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. Blood eosinophilia is common and bronchoalveolar lavage may also demonstrate eosinophils. Definitive diagnosis consists of recovery of larvae from respiratory secretions or bronchoalveolar lavage fluid, although such procedures are rarely needed.",
"   </p>",
"   <p>",
"    Stool examination and serologic tests are not helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific anthelminthic therapy for the pulmonary involvement is generally",
"    <strong>",
"     not",
"    </strong>",
"    required since the illness is usually mild and self-limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2841596\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous larva migrans (CLM) occurs as a result of human infection with the larvae of the dog or cat hookworm; it may also be caused by other animal hookworms. The terms CLM and &lsquo;creeping eruption&rsquo; refer to subcutaneous intradermal migration of nonhuman filariform zoonotic larvae that may manifest as a cutaneous track. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infection occurs most frequently in the tropical and subtropical countries of Southeast Asia, Africa, South America, Caribbean, and the southeastern parts of the United States. Larvae are found on sandy beaches, in sand boxes, and under dwellings. Individuals at greatest risk include travelers, children, swimmers and laborers whose activities bring their skin in contact with contaminated soil. (See",
"      <a class=\"local\" href=\"#H31956589\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The hookworm life cycle in the definitive host is very similar to the hookworm life cycle for human species (",
"      <a class=\"graphic graphic_figure graphicRef61675 \" href=\"mobipreview.htm?8/7/8310\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef73772 \" href=\"mobipreview.htm?2/14/2279\">",
"       figure 2",
"      </a>",
"      ). Humans may become infected when filariform larvae in the soil penetrate the skin. The larvae of most species cannot mature within the human host; they migrate within the epidermis and produce an inflammatory reaction. (See",
"      <a class=\"local\" href=\"#H31956718\">",
"       'Life cycle'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CLM occurs most frequently on the lower extremities. Initially a pruritic erythematous papule develops at the site of each larval penetration. Two to three days later, intensely pruritic, elevated, serpiginous, reddish-brown lesions appear as the larvae migrate at a rate of several millimeters per day (",
"      <a class=\"graphic graphic_picture graphicRef60144 \" href=\"mobipreview.htm?39/63/40944\">",
"       picture 1",
"      </a>",
"      ). The lesions generally resolve spontaneously within two to eight weeks in the absence of specific therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cutaneous disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of CLM with anthelminthic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); treatment is helpful for relieving symptoms and reducing the likelihood of bacterial superinfection. We suggest systemic treatment with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      orally once daily for one or two days) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg orally for three days) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical agents are an alternative treatment option though they can be difficult to obtain and use. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematogenous dissemination of larvae to the lungs is relatively rare. The most frequent manifestation is dry cough that starts about one week after cutaneous penetration. Specific anthelminthic therapy for the pulmonary involvement is generally not required since the illness is usually mild and self-limited. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/1\">",
"      Brenner MA, Patel MB. Cutaneous larva migrans: the creeping eruption. Cutis 2003; 72:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/2\">",
"      Monsel G, Caumes E. Recent developments in dermatological syndromes in returning travelers. Curr Opin Infect Dis 2008; 21:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/3\">",
"      French SJ, Lindo JF. Severe cutaneous larva migrans in a traveler to Jamaica, West Indies. J Travel Med 2003; 10:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/4\">",
"      Sherman SC, Radford N. Severe infestation of cutaneous larva migrans. J Emerg Med 2004; 26:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/5\">",
"      Santar&eacute;m VA, Giuffrida R, Zanin GA. [Cutaneous larva migrans: reports of pediatric cases and contamination by Ancylostoma spp larvae in public parks in Taciba, S&atilde;o Paulo State]. Rev Soc Bras Med Trop 2004; 37:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/6\">",
"      Wilson ME, Chen LH. Dermatologic Infectious Diseases in International Travelers. Curr Infect Dis Rep 2004; 6:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/7\">",
"      Centers for Disease Control and Prevention (CDC). Outbreak of cutaneous larva migrans at a children's camp--Miami, Florida, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/8\">",
"      Caumes E, Carri&egrave;re J, Guermonprez G, et al. Dermatoses associated with travel to tropical countries: a prospective study of the diagnosis and management of 269 patients presenting to a tropical disease unit. Clin Infect Dis 1995; 20:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/9\">",
"      Davies HD, Sakuls P, Keystone JS. Creeping eruption. A review of clinical presentation and management of 60 cases presenting to a tropical disease unit. Arch Dermatol 1993; 129:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/10\">",
"      Gillespie SH. Cutaneous Larva Migrans. Curr Infect Dis Rep 2004; 6:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/11\">",
"      Lederman ER, Weld LH, Elyazar IR, et al. Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network. Int J Infect Dis 2008; 12:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/12\">",
"      Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveller. Br J Dermatol 2001; 145:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/13\">",
"      Tan SK, Liu TT. Cutaneous larva migrans complicated by L&ouml;ffler syndrome. Arch Dermatol 2010; 146:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/14\">",
"      Jelinek T, Maiwald H, Nothdurft HD, L&ouml;scher T. Cutaneous larva migrans in travelers: synopsis of histories, symptoms, and treatment of 98 patients. Clin Infect Dis 1994; 19:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/15\">",
"      Caumes E, Danis M. From creeping eruption to hookworm-related cutaneous larva migrans. Lancet Infect Dis 2004; 4:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/16\">",
"      Heukelbach J, Feldmeier H. Epidemiological and clinical characteristics of hookworm-related cutaneous larva migrans. Lancet Infect Dis 2008; 8:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/17\">",
"      Archer M. Late presentation of cutaneous larva migrans: a case report. Cases J 2009; 2:7553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/18\">",
"      Siriez JY, Angoulvant F, Buffet P, et al. Individual variability of the cutaneous larva migrans (CLM) incubation period. Pediatr Dermatol 2010; 27:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/19\">",
"      Yap FB. Cutaneous larva migrans in Hospital Kuala Lumpur, Malaysia: rate of correct diagnosis made by the referring primary care doctors. Trans R Soc Trop Med Hyg 2011; 105:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/20\">",
"      Jackson A, Heukelbach J, Calheiros CM, et al. A study in a community in Brazil in which cutaneous larva migrans is endemic. Clin Infect Dis 2006; 43:e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/21\">",
"      Richey TK, Gentry RH, Fitzpatrick JE, Morgan AM. Persistent cutaneous larva migrans due to Ancylostoma species. South Med J 1996; 89:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/22\">",
"      Opie KM, Heenan PJ, Delaney TA, Rohr JB. Two cases of eosinophilic pustular folliculitis associated with parasitic infestations. Australas J Dermatol 2003; 44:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/23\">",
"      Caumes E, Ly F, Bricaire F. Cutaneous larva migrans with folliculitis: report of seven cases and review of the literature. Br J Dermatol 2002; 146:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/24\">",
"      Hochedez P, Caumes E. Hookworm-related cutaneous larva migrans. J Travel Med 2007; 14:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/25\">",
"      Feldmeier H, Schuster A. Mini review: Hookworm-related cutaneous larva migrans. Eur J Clin Microbiol Infect Dis 2012; 31:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/26\">",
"      Rivera-Roig V, S&aacute;nchez JL, Hillyer GV. Hookworm folliculitis. Int J Dermatol 2008; 47:246.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections. Medical Lett Drugs Ther; August 2004. www.medletter.com/freedocs/parasitic.pdf (Accessed on March 08, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/28\">",
"      Albanese G, Venturi C, Galbiati G. Treatment of larva migrans cutanea (creeping eruption): a comparison between albendazole and traditional therapy. Int J Dermatol 2001; 40:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/29\">",
"      Veraldi S, Rizzitelli G. Effectiveness of a new therapeutic regimen with albendazole in cutaneous larva migrans. Eur J Dermatol 1999; 9:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/30\">",
"      Caumes E. Efficacy of albendazole ointment on cutaneous larva migrans in 2 young children. Clin Infect Dis 2004; 38:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/31\">",
"      WRIGHT DO, GOLD EM. L&ouml;ffler's syndrome associated with creeping eruption (cutaneous helminthiasis). Arch Intern Med (Chic) 1946; 78:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/32\">",
"      KALMON EH. Creeping eruption associated with transient pulmonary infiltrations. Radiology 1954; 62:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/33\">",
"      MUHLEISEN JP. Demonstration of pulmonary migration of the causative organism of creeping eruption. Ann Intern Med 1953; 38:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/34\">",
"      Butland RJ, Coulson IH. Pulmonary eosinophilia associated with cutaneous larva migrans. Thorax 1985; 40:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36229/abstract/35\">",
"      Guill MA, Odom RB. Larva migrans complicated by Loeffler's syndrome. Arch Dermatol 1978; 114:1525.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5718 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36229=[""].join("\n");
var outline_f35_24_36229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2841596\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31956589\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31956718\">",
"      Life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CUTANEOUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2841596\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5718\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5718|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/39/33393\" title=\"diagnostic image 1\">",
"      CXR - pulmonary involvement of CLM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5718|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/7/8310\" title=\"figure 1\">",
"      Hookworm life cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/14/2279\" title=\"figure 2\">",
"      Cutaneous larva migrans life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5718|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/63/40944\" title=\"picture 1\">",
"      Cutaneous larva migrans",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/28/42437?source=related_link\">",
"      Hookworm infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/26/36263?source=related_link\">",
"      Loiasis (Loa loa infection)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/8/44168?source=related_link\">",
"      Miscellaneous nematodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/43/20152?source=related_link\">",
"      Skin lesions in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36230="Subcutaneous nodules in blastomycosis";
var content_f35_24_36230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Subcutaneous nodules caused by Blastomyces dermatitidis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcutaneous nodules with superficial crusts due to blastomycosis on the thigh of a young man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Bradsher RW, Bariola JR. Blastomycosis. In: Essentials of Clinical Mycology, 2nd ed, Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (Eds), Springer, New York City 2011; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36230=[""].join("\n");
var outline_f35_24_36230=null;
var title_f35_24_36231="Tricyclic antidepressant poisoning";
var content_f35_24_36231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tricyclic antidepressant poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36231/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36231/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36231/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36231/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36231/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/24/36231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;From the late 1950s until the late 1980s, tricyclic antidepressants (TCAs) were used extensively in the management of a range of psychiatric disorders. Although selective serotonin reuptake inhibitors (SSRIs) have become first line therapy in the management of depression, TCAs are still used for this indication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .) TCAs are also used in the treatment of panic disorder, obsessive compulsive disorder, and chronic pain syndromes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TCA intoxication will be discussed here. A summary table to facilitate the emergent management of TCA overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef64294 \" href=\"mobipreview.htm?1/18/1325\">",
"     table 1",
"    </a>",
"    ). The general approach to a patient with known or suspected drug intoxication is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;TCAs have several important cellular effects, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inhibition of presynaptic neurotransmitter reuptake (norepinephrine and serotonin)",
"     </li>",
"     <li>",
"      Blockade of cardiac fast sodium channels",
"     </li>",
"     <li>",
"      Antagonism of central and peripheral muscarinic acetylcholine receptors",
"     </li>",
"     <li>",
"      Antagonism of peripheral alpha-1 adrenergic receptors",
"     </li>",
"     <li>",
"      Antagonism of histamine (H1) receptors",
"     </li>",
"     <li>",
"      Antagonism of CNS gamma-aminobutyric acid (GABA) A receptors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapeutic doses of TCAs are rapidly absorbed from the gastrointestinal tract, reaching maximal plasma concentrations within two to eight hours. Following overdose, antimuscarinic effects may delay gastric emptying and absorption, significantly prolonging the time to peak plasma concentration.",
"   </p>",
"   <p>",
"    TCAs are lipophilic and have a large volume of distribution (Vd). The plasma fraction of drug is usually highly bound to alpha-1 acid glycoprotein. The combination of a large Vd and protein binding means that forced diuresis, dialysis, and hemoperfusion have no role in the management of TCA overdose.",
"   </p>",
"   <p>",
"    TCAs are primarily metabolized by the liver. Some drugs of this class have active metabolites, which may persist for 12 to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Half-life varies according to drug and ranges from 7 to 58 hours, but can be prolonged in overdose. Seventy percent of the total dose is excreted via the kidney as inactive metabolites; the remainder is excreted via the biliary system. Enterohepatic recirculation can delay final elimination of a large fraction of the drug, prolonging absorption and potentially increasing toxicity following overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting signs of TCA overdose typically include CNS sedation (from antihistaminic effects), but may also include confusion, delirium, or hallucinations. Arrhythmias, cardiac conduction delays, hypotension, and anticholinergic toxicity (hyperthermia, flushing, dilated pupils, intestinal ileus, urinary retention, and sinus tachycardia) are also common (",
"    <a class=\"graphic graphic_table graphicRef64294 \" href=\"mobipreview.htm?1/18/1325\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/2,3,6,7\">",
"     2,3,6,7",
"    </a>",
"    ]. Patients who present immediately after a TCA overdose may initially be well-appearing, only to deteriorate rapidly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cardiac toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most prominent electrocardiographic manifestation of TCA toxicity is widening of the QRS interval. Other findings include prolongation of the PR and QT intervals, block within the His-Purkinje system, and intraventricular conduction delay (eg, bundle branch block). Because of its relatively longer refractory period, the right bundle branch is especially sensitive to block in the setting of TCA overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/8\">",
"     8",
"    </a>",
"    ]. These conduction system abnormalities may contribute to the hypotension seen in TCA poisoning.",
"   </p>",
"   <p>",
"    Cardiac conduction abnormalities occur because TCAs inhibit the fast sodium channels in the His-Purkinje system as well as the atrial and ventricular myocardium. This decreases conduction velocity, increases the duration of repolarization, and prolongs absolute refractory periods (",
"    <a class=\"graphic graphic_figure graphicRef61989 \" href=\"mobipreview.htm?34/63/35827\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These effects are similar to those of the class 1A antiarrhythmic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sinus tachycardia is common in overdose, likely as a result of anticholinergic (vagolytic) effects of the drug and a reflex tachycardia due to hemodynamic decompensation.",
"   </p>",
"   <p>",
"    Ventricular tachycardia and ventricular fibrillation (VT and VF) occur in approximately 4 percent of TCA overdose cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/11\">",
"     11",
"    </a>",
"    ]. VT and VF are more common in severe poisonings, especially those complicated by acidosis, hypotension, and extreme QRS prolongation. Although QT prolongation is common in TCA overdose, the polymorphic ventricular tachycardia associated with QT prolongation, Torsade de Pointes (TdP), is not. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TCA overdose-related mortality is due largely to refractory hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Mechanisms that may contribute include decreased contractility from reduced calcium influx into ventricular myocytes, due to blockade of rapid sodium channels, and peripheral vasodilation from blockade of alpha 1 adrenergic receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     CNS toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental status changes, such as obtundation (due to antihistaminic effects) or less frequently, delirium (due to anticholinergic effects), are common following TCA overdose. Seizures may result from the antagonist effects of TCAs on the GABA-A receptor (",
"    <a class=\"graphic graphic_table graphicRef64294 \" href=\"mobipreview.htm?1/18/1325\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequent reassessment of patients with known or suspected TCA intoxication is essential, as their level of alertness can change quickly. Patients may manifest psychomotor agitation and delirium in the initial hours after ingestion, only to develop progressive obtundation and coma in later stages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation is directed toward establishing the diagnosis and estimating the severity of intoxication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine laboratory evaluation of the poisoned patient should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An electrocardiogram, to assess for cardiac conduction abnormalities (this is particularly important in TCA ingestions)",
"     </li>",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtaining an electrocardiogram (ECG) immediately upon presentation is essential in patients with known or suspected TCA poisoning (",
"    <a class=\"graphic graphic_table graphicRef64294 \" href=\"mobipreview.htm?1/18/1325\">",
"     table 1",
"    </a>",
"    ). Arrhythmias from a TCA overdose can develop quickly and frequent serial ECGs should be obtained until the patient has been free of symptoms and any signs of cardiac toxicity for several hours. The following signs suggest cardiotoxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolongation of the QRS &gt;100 msec",
"     </li>",
"     <li>",
"      Abnormal morphology of the QRS (eg, deep, slurred S wave in leads I and AVL)",
"     </li>",
"     <li>",
"      Abnormal size and ratio of the R and S waves in lead AVR: R wave in AVR &gt;3 mm; R to S ratio in AVR &gt;0.7.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These signs are used as important tools in diagnosis, risk stratification, and management (",
"    <a class=\"graphic graphic_waveform graphicRef63490 \" href=\"mobipreview.htm?25/57/26515\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76352 \" href=\"mobipreview.htm?9/49/10001\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    None of these electrocardiographic criteria is completely reliable in the individual patient, and significant toxicity can occur despite falsely reassuring indices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/15\">",
"     15",
"    </a>",
"    ]. Preexisting conduction delay may also complicate interpretation. Despite these limitations, we view prolongation of the QRS duration &gt;100 msec as a sign of potential cardiac toxicity, and as an indication for a trial of therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Sodium bicarbonate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     QRS duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one prospective series, patients with a QRS duration less than 100 msec did not suffer a seizure or a ventricular arrhythmia; those with a QRS duration &gt;100 msec had a 26 percent chance of seizure, and those with a QRS duration &gt;160 msec had a 50 percent chance of a ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/16\">",
"     16",
"    </a>",
"    ]. Although some authors have questioned the utility and reproducibility of QRS duration analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ], other studies confirm the predictive value of QRS duration for seizure and ventricular arrhythmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Terminal frontal plane QRS vector",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed right ventricular activation from intra- and interventricular conduction delays in the setting of TCA overdose has been shown to cause rightward shift in the terminal 40 msec frontal plane QRS vector [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/8,19,21,22\">",
"     8,19,21,22",
"    </a>",
"    ]. Accurate measurement of this parameter requires computerized interpretation, but in qualitative terms this shift manifests as a deep, slurred S wave in leads I and AVL, and an R wave in lead AVR (",
"    <a class=\"graphic graphic_waveform graphicRef63490 \" href=\"mobipreview.htm?25/57/26515\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76352 \" href=\"mobipreview.htm?9/49/10001\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18308?source=see_link\">",
"     \"Basic approach to delayed intraventricular conduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of this differential conduction delay, R wave amplitude in lead AVR (RAVR) and the ratio of R:S wave amplitude in AVR",
"    <span class=\"nowrap\">",
"     (R/SAVR)",
"    </span>",
"    are significantly higher in TCA overdose patients than matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/19\">",
"     19",
"    </a>",
"    ]. One cohort study noted that the risk of seizures and ventricular arrhythmias were significantly increased in patients with RAVR &gt;3 mm,",
"    <span class=\"nowrap\">",
"     R/SAVR",
"    </span>",
"    &gt;0.7, and QRS duration &gt;100 msec [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Measurement of TCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Qualitative (urine) and quantitative (blood) TCA testing has limited therapeutic or prognostic utility in the acute setting. A positive qualitative test only confirms use, not overdose. Quantitative blood levels are not only poor predictors of systemic toxicity, but are usually not available within a clinically relevant time frame [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/16\">",
"     16",
"    </a>",
"    ]. In general, serum concentrations greater than 1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    tend to correlate with increased organ dysfunction. However, significant toxicity can occur at far lower values, especially in children and in patients taking TCAs on a chronic basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/19,23,24\">",
"     19,23,24",
"    </a>",
"    ]. Furthermore, false positive TCA testing can result from cross-reactivity of tricyclic antidepressant immunoassays with other medications, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Initial resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial management of the patient with a TCA overdose centers around securing the patient's airway, breathing, and circulation. TCA poisoned patients are frequently moribund and require intubation for airway protection and ventilation. Supplemental oxygen should be administered as needed. A summary table to facilitate the emergent management of TCA overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef64294 \" href=\"mobipreview.htm?1/18/1325\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additional therapy consists primarily of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isotonic saline to address hypotension.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       Sodium bicarbonate",
"      </a>",
"      to address other cardiovascular toxicities.",
"     </li>",
"     <li>",
"      Alpha adrenergic vasopressors (such as norepinephrine or neosynephrine) to address hypotension refractory to aggressive fluid resuscitation and bicarbonate infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although TCAs possess some anticholinergic properties, cardiac toxicity is most prominent.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"     Physostigmine",
"    </a>",
"    may worsen cardiac function and is associated with cardiac arrest in the setting of TCA overdose; physostigmine should not be given if a TCA ingestion is known or suspected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/29\">",
"     29",
"    </a>",
"    ]. The role of physostigmine in anticholinergic overdose is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sodium bicarbonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with hypertonic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is warranted in patients with TCA poisoning who develop widening of the QRS interval &gt;100 msec or a ventricular arrhythmia. Most patients with TCA-induced QRS interval prolongation respond to bicarbonate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial dose is 1 to 2",
"    <span class=\"nowrap\">",
"     mEq/kg",
"    </span>",
"    given as a rapid IV push through a large bore IV catheter. In adults, one common dose is two to three vials or prefilled syringes (50 mL each) of 8.4 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . It is useful to run a continuous 12-lead ECG during the infusion, to demonstrate the presence (or absence) of narrowing of the QRS complex, a decrease in the R wave amplitude in lead AVR, or resolution of the arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef63490 \" href=\"mobipreview.htm?25/57/26515\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef76352 \" href=\"mobipreview.htm?9/49/10001\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the QRS narrows after bolus therapy, begin a continuous IV infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . We mix 125 to 150 mEq of sodium bicarbonate in 1 liter of 5 percent dextrose (D5W), and infuse at 250",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    in adults. The same fluid should be given to children at twice the maintenance fluid rate. Excessive fluid resuscitation, which can contribute to the pulmonary complications sometimes associated with TCA overdose, must be avoided.",
"   </p>",
"   <p>",
"    Should a widened QRS interval fail to narrow following bolus therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , we still suggest that an IV infusion of sodium bicarbonate be started. Failure of a widened QRS to respond to bolus therapy does not exclude the possibility of TCA toxicity, and systemic acidemia potentiates the effects of TCA poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/31\">",
"     31",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Most toxicologists taper bicarbonate therapy after the resolution of ECG changes, which may occur over hours to days. One reasonable approach is to reduce the infusion by about 25 percent per hour over four hours. Should the QRS interval widen during tapering, give an additional bolus of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    and restart the original infusion.",
"   </p>",
"   <p>",
"    Frequent arterial blood pH measurements should be obtained during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    ; a reasonable goal pH is 7.50 to 7.55. Volume overload, hypokalemia, hypernatremia, and metabolic alkalosis may result from prolonged bicarbonate infusions, and clinical and laboratory parameters must be followed closely to avoid these complications.",
"   </p>",
"   <p>",
"    The rationale for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy is based in part upon animal studies showing that sodium bicarbonate narrows the QRS complex, improves systolic blood pressure, and controls ventricular arrhythmias in TCA overdose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/30,33-37\">",
"     30,33-37",
"    </a>",
"    ]. There is a conspicuous absence of randomized, prospective trials in humans, and most evidence of efficacy is based upon clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/31,38\">",
"     31,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    is probably due to both an increase in serum pH and the increase in extracellular sodium. The increase in serum pH favors the neutral form of the drug, making it less available to bind to sodium channels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/33\">",
"     33",
"    </a>",
"    ]. Increasing the extracellular sodium concentration increases the electrochemical gradient across cardiac cell membranes, potentially attenuating the TCA-induced blockade of rapid sodium channels. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressors are indicated in patients with hypotension refractory to fluid and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    therapy. Direct acting alpha-adrenergic agonists (eg, norepinephrine or neosynephrine) are preferred because they counter the alpha-adrenergic antagonist effects of TCAs. A retrospective study of TCA poisoned patients demonstrated a universal response to norepinephrine infusion, including patients who had previously failed to respond to dopamine infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the airway, breathing and circulation have been secured, attention may be turned to gastrointestinal decontamination. Unless bowel obstruction, ileus, or perforation is suspected, we recommend 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of charcoal (up to 50 g) in patients who present within two hours of ingestion. Charcoal should be withheld in patients who are sedated and may not be able to protect their airway, unless endotracheal intubation is performed first. Endotracheal intubation, however, should not be performed solely for the purpose of giving charcoal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=see_link\">",
"     \"Enhanced elimination of poisons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Antiarrhythmic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    is the mainstay of antiarrhythmic therapy in TCA intoxication. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Sodium bicarbonate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Concerns surround the use of all classes of antiarrhythmic drugs in the setting of TCA poisoning. Class IA (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) and IC agents are",
"    <strong>",
"     CONTRAINDICATED",
"    </strong>",
"    given their inhibition of rapid sodium channels, which is similar to that induced by TCAs. Class III agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) are poorly studied in this setting and QTc prolongation associated with these drugs makes them potentially dangerous. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     Lidocaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (class IB agents) have been evaluated with some encouraging results, but we do not advocate their routine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/10,42\">",
"     10,42",
"    </a>",
"    ]. Limited evidence supports the use of intravenous magnesium in patients with wide complex tachycardia unresponsive to other antiarrhythmic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36231/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antiepileptic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines remain the treatment of choice for TCA-induced seizures. Such seizures are likely caused in large part by a decrease of central GABA receptor inhibition. It is therefore logical to treat seizures with GABA agonists rather than sodium channel blocking drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     Flumazenil",
"    </a>",
"    is contraindicated in known or suspected TCA use. In patients who acutely coingest TCAs and benzodiazepines, flumazenil may lower the seizure threshold. In patients with a TCA ingestion who chronically use benzodiazepines, flumazenil can induce benzodiazepine-withdrawal seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pediatric considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;TCA poisoning in the pediatric population generally follows a course similar to that in adults, and the above-mentioned assessment and treatment recommendations apply. In any pediatric ingestion, healthcare workers should ascertain how the child got access to the medication, counseling caregivers regarding medication safety as appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with an alteration in mental status, hypotension, cardiac conduction abnormalities, or seizures should be admitted to an intensive care unit. Patients with mild symptoms, such as an isolated tachycardia without evidence of conduction abnormalities (ie, QRS &lt;100 msec), could conceivably be admitted to a telemetry setting. Asymptomatic patients who have no conduction abnormalities on ECG and are monitored for at least six hours in an acute care setting can be safely discharged or transferred to a psychiatric service for evaluation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate the emergent management of TCA overdose is provided (",
"    <a class=\"graphic graphic_table graphicRef64294 \" href=\"mobipreview.htm?1/18/1325\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricyclic antidepressant usage remains prevalent. Symptoms of TCA intoxication generally consist of cardiac conduction abnormalities, obtundation, seizures, and anticholinergic toxicity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link\">",
"       \"Anticholinergic poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ECG is the most valuable tool in determining the extent of poisoning. The following signs suggest cardiotoxicity:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prolongation of the QRS &gt;100 msec",
"     </li>",
"     <li>",
"      Abnormal morphology of the QRS (eg, deep, slurred S wave in leads I and AVL)",
"     </li>",
"     <li>",
"      Abnormal size and ratio of the R and S waves in lead AVR: R wave in AVR &gt;3 mm; R to S ratio in AVR &gt;0.7. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of symptomatic patients consists primarily of IV fluid resuscitation for hypotension and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      for QRS duration &gt;100 msec or a ventricular arrhythmia. The initial dose of sodium bicarbonate is 1 to 2",
"      <span class=\"nowrap\">",
"       meq/kg.",
"      </span>",
"      In adults, this may be given as two to three 50 mEq (50 mL) vials or prefilled syringes of 8.4 percent sodium bicarbonate given as a rapid IV push through a large bore IV. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Initial resuscitation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Sodium bicarbonate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/1\">",
"      Franssen EJ, Kunst PW, Bet PM, et al. Toxicokinetics of nortriptyline and amitriptyline: two case reports. Ther Drug Monit 2003; 25:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/2\">",
"      Lynch R. Tricyclic antidepressant overdose. Emerg Med J 2002; 19:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/3\">",
"      Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J 2001; 18:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/4\">",
"      Jarvis MR. Clinical pharmacokinetics of tricyclic antidepressant overdose. Psychopharmacol Bull 1991; 27:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/5\">",
"      Spiker DG, Biggs JT. Tricyclic antidepressants. Prolonged plasma levels after overdose. JAMA 1976; 236:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/6\">",
"      Biggs JT, Spiker DG, Petit JM, Ziegler VE. Tricyclic antidepressant overdose: incidence of symptoms. JAMA 1977; 238:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/7\">",
"      Glauser J. Tricyclic antidepressant poisoning. Cleve Clin J Med 2000; 67:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/8\">",
"      Niemann JT, Bessen HA, Rothstein RJ, Laks MM. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. Am J Cardiol 1986; 57:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/9\">",
"      Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 1984; 35:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/10\">",
"      Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning. Management of arrhythmias. Med Toxicol 1986; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/11\">",
"      Goldberg RJ, Capone RJ, Hunt JD. Cardiac complications following tricyclic antidepressant overdose. Issues for monitoring policy. JAMA 1985; 254:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/12\">",
"      Callaham M, Kassel D. Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. Ann Emerg Med 1985; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/13\">",
"      Shannon M, Merola J, Lovejoy FH Jr. Hypotension in severe tricyclic antidepressant overdose. Am J Emerg Med 1988; 6:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/14\">",
"      Merigian KS, Hedges JR, Kaplan LA, et al. Plasma catecholamine levels in cyclic antidepressant overdose. J Toxicol Clin Toxicol 1991; 29:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/15\">",
"      Harrigan RA, Brady WJ. ECG abnormalities in tricyclic antidepressant ingestion. Am J Emerg Med 1999; 17:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/16\">",
"      Boehnert MT, Lovejoy FH Jr. Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med 1985; 313:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/17\">",
"      Foulke GE, Albertson TE. QRS interval in tricyclic antidepressant overdosage: inaccuracy as a toxicity indicator in emergency settings. Ann Emerg Med 1987; 16:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/18\">",
"      Buckley NA, O'Connell DL, Whyte IM, Dawson AH. Interrater agreement in the measurement of QRS interval in tricyclic antidepressant overdose: implications for monitoring and research. Ann Emerg Med 1996; 28:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/19\">",
"      Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med 1995; 26:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/20\">",
"      Liebelt EL, Ulrich A, Francis PD, Woolf A. Serial electrocardiogram changes in acute tricyclic antidepressant overdoses. Crit Care Med 1997; 25:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/21\">",
"      Caravati EM, Bossart PJ. Demographic and electrocardiographic factors associated with severe tricyclic antidepressant toxicity. J Toxicol Clin Toxicol 1991; 29:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/22\">",
"      Wolfe TR, Caravati EM, Rollins DE. Terminal 40-ms frontal plane QRS axis as a marker for tricyclic antidepressant overdose. Ann Emerg Med 1989; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/23\">",
"      Petit JM, Spiker DG, Ruwitch JF, et al. Tricyclic antidepressant plasma levels and adverse effects after overdose. Clin Pharmacol Ther 1977; 21:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/24\">",
"      Spiker DG, Weiss AN, Chang SS, et al. Tricyclic antidepressant overdose: clinical presentation and plasma levels. Clin Pharmacol Ther 1975; 18:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/25\">",
"      Chattergoon DS, Verjee Z, Anderson M, et al. Carbamazepine interference with an immune assay for tricyclic antidepressants in plasma. J Toxicol Clin Toxicol 1998; 36:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/26\">",
"      Fleischman A, Chiang VW. Carbamazepine overdose recognized by a tricyclic antidepressant assay. Pediatrics 2001; 107:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/27\">",
"      Hendrickson RG, Morocco AP. Quetiapine cross-reactivity among three tricyclic antidepressant immunoassays. J Toxicol Clin Toxicol 2003; 41:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/28\">",
"      Sloan KL, Haver VM, Saxon AJ. Quetiapine and false-positive urine drug testing for tricyclic antidepressants. Am J Psychiatry 2000; 157:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/29\">",
"      Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med 1980; 9:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/30\">",
"      Blackman K, Brown SG, Wilkes GJ. Plasma alkalinization for tricyclic antidepressant toxicity: a systematic review. Emerg Med (Fremantle) 2001; 13:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/31\">",
"      Hoffman JR, Votey SR, Bayer M, Silver L. Effect of hypertonic sodium bicarbonate in the treatment of moderate-to-severe cyclic antidepressant overdose. Am J Emerg Med 1993; 11:336.",
"     </a>",
"    </li>",
"    <li>",
"     Liebelt EL. Chapter 73: Cyclic antidepressants. In: Goldfrank's Toxicologic Emergencies, 9th, Nelson LS, et al. (Ed), McGraw-Hill, New York 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/33\">",
"      Sasyniuk BI, Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. J Pharmacol Exp Ther 1984; 231:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/34\">",
"      Sasyniuk BI, Jhamandas V, Valois M. Experimental amitriptyline intoxication: treatment of cardiac toxicity with sodium bicarbonate. Ann Emerg Med 1986; 15:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/35\">",
"      McCabe JL, Cobaugh DJ, Menegazzi JJ, Fata J. Experimental tricyclic antidepressant toxicity: a randomized, controlled comparison of hypertonic saline solution, sodium bicarbonate, and hyperventilation. Ann Emerg Med 1998; 32:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/36\">",
"      Pentel P, Benowitz N. Efficacy and mechanism of action of sodium bicarbonate in the treatment of desipramine toxicity in rats. J Pharmacol Exp Ther 1984; 230:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/37\">",
"      Brown TC. Tricyclic antidepressant overdosage: experimental studies on the management of circulatory complications. Clin Toxicol 1976; 9:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/38\">",
"      Brown TC. Sodium bicarbonate treatment for tricyclic antidepressant arrhythmias in children. Med J Aust 1976; 2:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/39\">",
"      Tran TP, Panacek EA, Rhee KJ, Foulke GE. Response to dopamine vs norepinephrine in tricyclic antidepressant-induced hypotension. Acad Emerg Med 1997; 4:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/40\">",
"      Bosse GM, Barefoot JA, Pfeifer MP, Rodgers GC. Comparison of three methods of gut decontamination in tricyclic antidepressant overdose. J Emerg Med 1995; 13:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/41\">",
"      Roy TM, Ossorio MA, Cipolla LM, et al. Pulmonary complications after tricyclic antidepressant overdose. Chest 1989; 96:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/42\">",
"      Mayron R, Ruiz E. Phenytoin: does it reverse tricyclic-antidepressant-induced cardiac conduction abnormalities? Ann Emerg Med 1986; 15:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/43\">",
"      Citak A, Soysal DD, U&ccedil;sel R, et al. Efficacy of long duration resuscitation and magnesium sulphate treatment in amitriptyline poisoning. Eur J Emerg Med 2002; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/44\">",
"      Knudsen K, Abrahamsson J. Magnesium sulphate in the treatment of ventricular fibrillation in amitriptyline poisoning. Eur Heart J 1997; 18:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36231/abstract/45\">",
"      Knudsen K, Abrahamsson J. Effects of magnesium sulfate and lidocaine in the treatment of ventricular arrhythmias in experimental amitriptyline poisoning in the rat. Crit Care Med 1994; 22:494.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 295 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36231=[""].join("\n");
var outline_f35_24_36231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cardiac toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CNS toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - QRS duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Terminal frontal plane QRS vector",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Measurement of TCA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Initial resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sodium bicarbonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Antiarrhythmic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antiepileptic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/295\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/295|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/63/35827\" title=\"figure 1\">",
"      Conduction system action potentials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/49/10001\" title=\"figure 2\">",
"      Tricyclic ECG changes B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/295|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/18/1325\" title=\"table 1\">",
"      Tricyclic antidepressant intoxication - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/295|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?25/57/26515\" title=\"waveform 1\">",
"      Electrocardiographic changes from tricyclic antidepressant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18308?source=related_link\">",
"      Basic approach to delayed intraventricular conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26695?source=related_link\">",
"      Enhanced elimination of poisons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36232="Chemical pleurodesis";
var content_f35_24_36232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemical pleurodesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36232/contributors\">",
"     John E Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36232/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36232/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/24/36232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleurodesis is a procedure that obliterates the pleural space to prevent recurrent pleural effusion or recurrent pneumothorax. It is most commonly performed by draining the effusion or intrapleural air and then inducing inflammation and fibrosis by either instilling a chemical irritant or performing mechanical abrasion.",
"   </p>",
"   <p>",
"    The use of a chemical irritant is known as chemical pleurodesis. Common questions about chemical pleurodesis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What are the indications?",
"     </li>",
"     <li>",
"      What are the contraindications?",
"     </li>",
"     <li>",
"      Which agent should be used?",
"     </li>",
"     <li>",
"      How is it performed?",
"     </li>",
"     <li>",
"      What are the potential complications?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an alternative to chemical pleurodesis, the pleural space can be mechanically abraded during thoracoscopy or thoracotomy. This is known as mechanical (or dry abrasion) pleurodesis. The indications, contraindications, choice of sclerosant, procedure, and complications of chemical pleurodesis will be reviewed here. The techniques of tube thoracostomy and pleural abrasion during thoracoscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H19#H19\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'VATS pleurodesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis has been used to manage malignant pleural effusions, refractory nonmalignant pleural effusions, and pneumothorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Malignant effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant pleural effusion is the most widely accepted indication for chemical pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/1\">",
"     1",
"    </a>",
"    ]. Identifying patients with malignant pleural effusions who should be considered for chemical pleurodesis and alternative options for managing malignant pleural effusions are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonmalignant effusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapy for nonmalignant pleural effusions is treatment of the underlying cause. Refractory nonmalignant pleural effusions sometimes require more invasive therapy, such as chemical pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful chemical pleurodesis has been reported in case reports of patients with pleural effusions caused by chronic ambulatory peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], yellow nail syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], chylothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/13-16\">",
"     13-16",
"    </a>",
"    ], nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/17\">",
"     17",
"    </a>",
"    ], lupus pleuritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/16\">",
"     16",
"    </a>",
"    ], hepatic hydrothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/16,18-21\">",
"     16,18-21",
"    </a>",
"    ], and heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In our experience, chemical pleurodesis via a chest tube is rarely successful in treating hepatic hydrothorax.",
"   </p>",
"   <p>",
"    The management of patients with refractory nonmalignant pleural effusion is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis successfully prevents the recurrence of primary and secondary spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. However, thoracoscopy with mechanical pleurodesis is generally preferred over chemical pleurodesis because it allows for simultaneous inspection for subpleural blebs and resection. In addition, mechanical pleurodesis does not expose the patient to possible risks related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    . On the other hand, if a patient with a pneumothorax prefers to avoid thoracoscopic surgery, chemical pleurodesis is a reasonable option.",
"   </p>",
"   <p>",
"    The management of spontaneous pneumothorax is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleurodesis will certainly fail if the lung cannot fully expand to the chest wall (eg, trapped or entrapped lung, interstitial pulmonary fibrosis, endobronchial obstruction) because successful pleurodesis requires contact of the visceral and parietal pleura. Chemical pleurodesis should therefore not be attempted when full lung expansion to the chest wall does not occur after therapeutic thoracentesis. Patients whose lungs cannot fully expand usually have radiographic evidence of a pneumothorax after thoracentesis or experience chest discomfort during thoracentesis before all pleural fluid is drained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before attempting pleural drainage, the diagnosis of trapped lung should be strongly suspected if the hemithorax with the effusion is reduced in size with shift of the mediastinum to the ipsilateral side. This radiographic appearance indicates that the pleural pressure on the side with the effusion is more negative than that on the contralateral side. Endobronchial obstruction and malignant encasement of the lung can cause the same constellation of findings or result in a midline mediastinum despite the presence of a large effusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional way to assess whether a trapped lung or lung entrapment is contributing to a pleural effusion is to perform pleural manometry at the time of therapeutic thoracentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Manometry measures pleural pressure changes as pleural fluid is withdrawn and allows the calculation of pleural elastance at the end of the procedure. A final value for pleural elastance &ge;19 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O per liter of fluid removed indicates a high likelihood of an unexpandable lung and predicts pleurodesis failure. In centers that can standardize the technique and produce reliable results, pleural manometry provides helpful information to identify an entrapped or trapped lung [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis and management of pleural causes of unexpandable lung\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No specific chemical characteristic of pleural fluid has sufficient predictive properties to be used to exclude individual patients from consideration for pleurodesis. In patients with malignant pleural effusions, certain chemical characteristics of pleural fluid make successful pleurodesis less likely, including pleural pH less than 7.20 or 7.30, pleural glucose less than 60",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and lactate dehydrogenase greater than 600",
"    <span class=\"nowrap\">",
"     U/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. A meta-analysis found that these criteria predicted pleurodesis failure with a sensitivity of only 55 to 59 percent and a specificity of 65 to 78 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CHOICE OF AGENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous chemical irritants have been used to induce pleurodesis. These include talc,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , iodopovidone,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , Corynebacterium parvum with parenteral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    acetate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    , interferon beta,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and Streptococcus pyogenes A3 (OK-432) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/39-44\">",
"     39-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristics of the agents most commonly used for chemical pleurodesis are described in the following sections. The choice among these agents is determined by several factors, including local expertise, availability of individual agents, and the underlying process for which chemical pleurodesis is needed. These issues are discussed further on the individual topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link\">",
"     \"Management of refractory nonmalignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Talc &ndash; Talc, a trilayered, magnesium sheet silicate, is the most effective and most commonly used agent. In a systematic review, talc was the chemical agent that most frequently resulted in complete success (no recurrence of pleural fluid)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/39\">",
"       39",
"      </a>",
"      ]. Numerous additional studies have confirmed that talc is the most effective agent for pleurodesis, including a large meta-analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. Taken together, these studies indicate that successful pleurodesis occurs in greater than 90 percent of patients treated with talc. However, such results have not been universal. One clinical trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       talc pleurodesis",
"      </a>",
"      reported a lower success rate of 78 percent, 30 days after pleurodesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link&amp;anchor=H2#H2\">",
"       \"Talc pleurodesis\", section on 'What is talc'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       Tetracycline",
"      </a>",
"      derivatives &ndash; Tetracycline is no longer available for pleurodesis in the United States; however, the tetracycline derivatives",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      are used for pleurodesis. Success rates with these agents in most reports are lower than those with talc with recurrence rates of 13 to 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/26,49\">",
"       26,49",
"      </a>",
"      ]. However, some clinicians prefer tetracycline derivatives for chemical pleurodesis in patients being treated for pneumothorax. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H20#H20\">",
"       \"Primary spontaneous pneumothorax in adults\", section on 'Chemical pleurodesis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"       Silver nitrate",
"      </a>",
"      and iodopovidone &ndash; Silver nitrate and iodopovidone have also been used for chemical pleurodesis. However, larger studies of these agents are necessary before their use can be recommended.",
"      <br/>",
"      <br/>",
"      The best evidence in favor of silver nitrate comes from a randomized trial that compared silver nitrate to talc. Sixty patients with a symptomatic malignant pleural effusion were randomly assigned to receive 5 g of talc slurry or a 0.5 percent solution of silver nitrate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/50\">",
"       50",
"      </a>",
"      ]. Both groups had similar efficacy at 30, 60 and 90 days, with no recurrence being observed in nearly all patients.",
"      <br/>",
"      <br/>",
"      The efficacy of iodopovidone for pleurodesis was examined in two separate case series; iodopovidone induced successful pleurodesis in 86 to 96 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"       Bleomycin",
"      </a>",
"      &ndash; Bleomycin is used less commonly for pleurodesis because of systemic toxicity and cost.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each patient's medications should be reviewed prior to performing pleurodesis. Concomitant use of glucocorticoids may decrease the success of chemical pleurodesis, because pleurodesis requires pleural inflammation and glucocorticoids are potent antiinflammatory agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Data regarding the effect of nonsteroidal antiinflammatory agents on pleurodesis are conflicting and limited to animal models. In our practice, we reduce or discontinue a patient's glucocorticoids and nonsteroidal antiinflammatory agents 24 to 48 hours prior to pleurodesis.",
"   </p>",
"   <p>",
"    Systemic anticoagulation is generally reversed for placement of a chest tube; it is not necessary to hold anticoagulation for chemical pleurodesis once the chest tube is in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROCEDURE VIA TUBE THORACOSTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pleural drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preparation for pleurodesis for pleural effusion, the pleural space is drained by tube thoracostomy, using a small bore (10 to 16 Fr) catheter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H4#H4\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously, it was common practice to delay pleurodesis until daily chest tube drainage was less than 150 mL. However, this delay appears to be unnecessary as noted in two small randomized trials and a case series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. In one study, for example, 25 patients with malignant pleural effusions were randomly assigned to standard (15 patients) or short-term (10 patients) protocols [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/56\">",
"     56",
"    </a>",
"    ]. In the standard protocol,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    was instilled only after the lung had completely expanded and the chest tube drainage was less than 150 mL per day. In the short-term protocol, the same dose of tetracycline was instilled as soon as there was complete lung expansion, which was usually within 24 hours. Pleurodesis was successful in 80 percent of patients in both groups.",
"   </p>",
"   <p>",
"    When pleurodesis is performed for pneumothorax, pleural air is drained until the lung is fully re-expanded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis is often painful; patients are usually pretreated with parenteral doses of an opiate (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ) and an",
"    <span class=\"nowrap\">",
"     anxiolytic/amnestic",
"    </span>",
"    agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ). Additionally, the British Thoracic Society guidelines for managing malignant pleural effusions recommend that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum 250 mg) should be instilled intrapleurally, just before administration of the sclerosant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/59\">",
"     59",
"    </a>",
"    ]. Postprocedure analgesia should be provided as necessary to maintain comfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Sclerosant agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically perform chemical pleurodesis using talc because of its demonstrated efficacy. As noted above, chemical pleurodesis can be performed using any of a number of different chemical agents, the most common of which are talc and the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    derivative,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Talc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis with talc can be accomplished with similar efficacy using insufflation (also called poudrage) during a thoracoscopy procedure or with slurry via tube thoracostomy as described above. Generally, the dose of talc administered intrapleurally is 4 g for insufflation and 5 g for slurry. When possible, size-calibrated talc that contains less than 10 percent of small particles (eg, 5 to 10 microns in diameter) should be used. Further details about the two procedures, talc doses, and analgesia are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link\">",
"     \"Talc pleurodesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Doxycycline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    used for intrapleural instillation is 500 mg dissolved in a total volume of 50 mL of normal saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    pleurodesis is often painful, although not more painful than other pleural sclerosants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/45\">",
"     45",
"    </a>",
"    ]. Some practitioners add a local analgesic agent (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , 25 mL [250 mg] of a 1 percent solution, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/55/40821?source=see_link\">",
"     mepivacaine",
"    </a>",
"    , 20 mL [400 mg] of 2 percent solution) to the doxycycline solution, although data supporting this is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Systemic absorption of the local anesthetic may be significant. In addition to local analgesia, systemic administration of an analgesic agent is usually necessary.",
"   </p>",
"   <p>",
"    At least one case of acute",
"    <span class=\"nowrap\">",
"     hypoxic/hypercapnic",
"    </span>",
"    respiratory failure has been reported after pleurodesis with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (300 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/63\">",
"     63",
"    </a>",
"    ]. Chest radiograph showed no pulmonary opacities and the presence of high peak ventilator pressures suggested acute bronchospasm due to an anaphylactic reaction. The patient improved in a few hours with ventilatory support and bronchodilator therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical pleurodesis may be performed at the time of thoracoscopy or at the bedside. Talc insufflation, which is performed during thoracoscopy, is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link&amp;anchor=H15#H15\">",
"     \"Talc pleurodesis\", section on 'Talc insufflation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When chemical pleurodesis is being done at the bedside via tube thoracostomy (eg, instillation of talc slurry or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ), the usual protocol is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Document good apposition of the pleural surfaces by chest radiograph.",
"     </li>",
"     <li>",
"      Ascertain adequate patient comfort and pain prevention.",
"     </li>",
"     <li>",
"      Administer the sclerosant agent (eg, talc,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ) via the chest tube. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link&amp;anchor=H18#H18\">",
"       \"Talc pleurodesis\", section on 'Talc slurry'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Doxycycline'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The chest tube should be clamped for one to two hours following instillation of the chemical irritant. Talc slurry distributes poorly; therefore, some clinicians rotate the patient. However, there is no evidence that such rotation improves the probability of successful pleurodesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/39\">",
"       39",
"      </a>",
"      ]. Studies with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"       tetracycline",
"      </a>",
"      also show no need to rotate the patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/64,65\">",
"       64,65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After the tube has been unclamped, chest tube suction is maintained (-20 cm H",
"      <sub>",
"       2",
"      </sub>",
"      0) for at least 24 hours.",
"     </li>",
"     <li>",
"      The traditional approach is to leave the chest tube in place until drainage is less than approximately 150 mL per 24 hours, although there are no scientific data to support this approach. The rationale is that ongoing pleural drainage helps to maintain apposition of the pleural surfaces and the chest tube is in place should repeat pleurodesis be needed. For example, if drainage is greater than 150 mL over 24 hours, repeat pleurodesis may be considered after 48 to 72 hours. Alternatively, some clinicians remove the chest tube within 24 hours after the instillation of talc or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , based on two small randomized trials showing no difference between the two approaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/56,66\">",
"       56,66",
"      </a>",
"      ]. The largest trial randomly assigned 41 patients with a malignant pleural effusion to have their chest tube removed either 24 hours or 72 hours after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"       talc pleurodesis",
"      </a>",
"      ; there was no difference in the success rate between the two groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/66\">",
"       66",
"      </a>",
"      ]. Pending larger studies, we suggest leaving the chest tube in place until the rate of drainage of pleural fluid is &lt;150",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"     </li>",
"     <li>",
"      If pleural fluid production persists despite chemical pleurodesis, use of an indwelling pleural catheter or thoracoscopic pleurodesis can be considered for secondary management. The options are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"       \"Management of malignant pleural effusions\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=see_link\">",
"       \"Management of refractory nonmalignant pleural effusions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse sequelae of chemical pleurodesis are fever, pain, and GI symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/45\">",
"     45",
"    </a>",
"    ]. Far less commonly, patients may experience respiratory failure, cardiovascular complications, a systemic inflammatory response, empyema, decreased lung volume, and dissemination of the chemical agent. Based on a meta-analysis (n = 1499), mortality is not increased among patients undergoing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    for a malignant pleural effusion compared with tube drainage alone or use of other sclerosants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the complications of pleurodesis appear to be related to the sclerosing process (eg, pain, cardiovascular side effects, systemic inflammation, empyema) and are likely to occur with all sclerosants, although some appear to be sclerosant and dose specific. As an example, increased systemic exposure to talc (eg, using more than 5 grams) appears to increase the risk of adverse sequelae, but does not increase the success rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link&amp;anchor=H22#H22\">",
"     \"Talc pleurodesis\", section on 'Complications and safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complication of acute respiratory failure, although rare, is more commonly seen after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    compared with other sclerosant agents. It is unlikely that the method of administration (insufflation versus slurry) plays a major role in the development of respiratory failure; however, the dose and mean particle size of talc may be important with smaller particles presenting an increased risk. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link&amp;anchor=H22#H22\">",
"     \"Talc pleurodesis\", section on 'Complications and safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications, such as arrhythmias, cardiac arrest, chest pain, myocardial infarction, and hypotension, have been reported following pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/53,67\">",
"     53,67",
"    </a>",
"    ]. However, it is unclear whether these complications are a result of the surgical procedure, co-morbid conditions, or the chemical irritant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mild systemic inflammatory reaction is common following chemical pleurodesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/67\">",
"     67",
"    </a>",
"    ]. As an example, in a retrospective study of 35 patients, patients who received talc insufflation via thoracoscopy had an increased temperature, white blood cell count, and c-reactive protein level compared to patients that underwent thoracoscopy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Empyema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial empyema has been reported following pleurodesis using talc slurry (zero to 11 percent), talc insufflation (zero to 3 percent), or rarely",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Local site infection is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lung volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term follow-up after talc insufflation has detected no difference in lung function when compared to tube thoracostomy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Long-term follow-up has similarly noted no impact on lung function in patients with pneumothorax who were treated thoracoscopically with talc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/27,73\">",
"     27,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dissemination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissemination of talc into BAL fluid and multiple organs has been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. The dissemination of talc into extrapulmonary organs appears to be dose-related [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A link between talc and cancer has been reported in individuals who mine and process talc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/78\">",
"     78",
"    </a>",
"    ]. This association has been attributed to asbestos within the talc. As a result, there is a theoretical concern that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/39/28274?source=see_link\">",
"     talc pleurodesis",
"    </a>",
"    could place the patient at increased risk for mesothelioma or lung cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the incidence of malignancy is not increased in patients who undergo talc pleurodesis and talc used for medical purposes is asbestos-free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36232/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant pleural effusion is the most common and widely accepted indication for chemical pleurodesis. In addition, chemical pleurodesis is sometimes used to manage refractory nonmalignant pleural effusions, recurrent primary spontaneous pneumothorax, and secondary spontaneous pneumothorax. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest systemic glucocorticoid therapy and nonsteroidal antiinflammatory drugs be reduced or discontinued prior to chemical pleurodesis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically hold these medications for 24 to 48 hours prior to pleurodesis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Patient preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The sclerosant agents used most commonly are talc and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      . Talc slurry administered via chest tube appears equally effective compared with aerosolized talc administered via insufflation during thoracoscopy (also called poudrage). Doxycycline is a less effective alternative to talc. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sclerosant agents'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=see_link\">",
"       \"Talc pleurodesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      After instillation of the sclerosant agent (eg, talc or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ), the chest tube is clamped for one to two hours, then suction is resumed. We suggest leaving the chest tube in place until fluid drainage is less than 150 mL per day rather than removal within the first 24 hours (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common short term adverse effects of chemical pleurodesis include pain, fever, and gastrointestinal symptoms. More rare adverse effects include respiratory failure, cardiovascular complications, a mild systemic inflammatory reaction, and empyema. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/1\">",
"      Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008; 83:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/2\">",
"      Sahn SA. Talc should be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/3\">",
"      Light RW. Talc should not be used for pleurodesis. Am J Respir Crit Care Med 2000; 162:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/4\">",
"      Ghio AJ, Roggli V, Light RW. Talc should not be used for pleurodesis in patients with nonmalignant pleural effusions. Am J Respir Crit Care Med 2001; 164:1741; author reply 1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/5\">",
"      Sudduth CD, Sahn SA. Pleurodesis for nonmalignant pleural effusions. Recommendations. Chest 1992; 102:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/6\">",
"      Glazer M, Berkman N, Lafair JS, Kramer MR. Successful talc slurry pleurodesis in patients with nonmalignant pleural effusion. Chest 2000; 117:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/7\">",
"      Benz RL, Schleifer CR. Hydrothorax in continuous ambulatory peritoneal dialysis: successful treatment with intrapleural tetracycline and a review of the literature. Am J Kidney Dis 1985; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/8\">",
"      Simmons LE, Mir AR. A review of management of pleuroperitoneal communication in five CAPD patients. Adv Perit Dial 1989; 5:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/9\">",
"      Rodriguez-Perez, JC, Palop, L, Plaza, C, et al. Diagnostic and treatment of massive hydrothorax in CAPD. Perit Dial Bull 1984; 4:49S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/10\">",
"      Posen, G, Sachs, H. Treatment of recurrent pleural effusion in dialysis patients by talc insufflation (abstract). Trans Am Soc Artif Intern Organs 1979; 8:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/11\">",
"      Nordkild P, Kromann-Andersen H, Struve-Christensen E. Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med Scand 1986; 219:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/12\">",
"      Hiller E, Rosenow EC 3rd, Olsen AM. Pulmonary manifestations of the yellow nail syndrome. Chest 1972; 61:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/13\">",
"      Adler RH, Levinsky L. Persistent chylothorax. Treatment by talc pleurodesis. J Thorac Cardiovasc Surg 1978; 76:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/14\">",
"      Lieberman J, Agliozzo CM. Intrapleural nitrogen mustard for treating chylous effusion of pulmonary lymphangioleiomyomatosis. Cancer 1974; 33:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/15\">",
"      Weissberg D. Talc pleurodesis : a controversial issue. Poumon Coeur 1981; 37:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/16\">",
"      Vargas FS, Milanez JR, Filomeno LT, et al. Intrapleural talc for the prevention of recurrence in benign or undiagnosed pleural effusions. Chest 1994; 106:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/17\">",
"      Jenkins PG, Shelp WD. Recurrent pleural transudate in the nephrotic syndrome. A new approach to treatment. JAMA 1974; 230:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/18\">",
"      Temes RT, Davis MS, Follis FM, et al. Videothoracoscopic treatment of hepatic hydrothorax. Ann Thorac Surg 1997; 64:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/19\">",
"      Mouroux J, H&eacute;buterne X, Perrin C, et al. Treatment of pleural effusion of cirrhotic origin by videothoracoscopy. Br J Surg 1994; 81:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/20\">",
"      Mouroux J, Perrin C, Venissac N, et al. Management of pleural effusion of cirrhotic origin. Chest 1996; 109:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/21\">",
"      Milanez de Campos JR, Filho LO, de Campos Werebe E, et al. Thoracoscopy and talc poudrage in the management of hepatic hydrothorax. Chest 2000; 118:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/22\">",
"      Spicer AJ, Fisher JA. Recurring pleural effusion in congestive heart failure treated by pleurodesis. J Ir Med Assoc 1969; 62:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/23\">",
"      Davidoff D, Naparstek Y, Eliakim M. The use of pleurodesis for intractable pleural effusion due to congestive heart failure. Postgrad Med J 1983; 59:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/24\">",
"      Audier M, Boutin C, Arnaud A, D'Journo J. [Case of cardiac effusion treated by pleuroscopic talc spray]. Mars Med 1967; 104:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/25\">",
"      Light RW, O'Hara VS, Moritz TE, et al. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax. Results of a Department of Veterans Affairs cooperative study. JAMA 1990; 264:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/26\">",
"      Almind M, Lange P, Viskum K. Spontaneous pneumothorax: comparison of simple drainage, talc pleurodesis, and tetracycline pleurodesis. Thorax 1989; 44:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/27\">",
"      Gy&ouml;rik S, Erni S, Studler U, et al. Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax. Eur Respir J 2007; 29:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/28\">",
"      Doelken P. Clinical implications of unexpandable lung due to pleural disease. Am J Med Sci 2008; 335:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/29\">",
"      Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med 2007; 13:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/30\">",
"      Doelken P, Huggins JT, Pastis NJ, Sahn SA. Pleural manometry: technique and clinical implications. Chest 2004; 126:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/31\">",
"      Feller-Kopman D, Parker MJ, Schwartzstein RM. Assessment of pleural pressure in the evaluation of pleural effusions. Chest 2009; 135:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/32\">",
"      Antunes G, Neville E. Management of malignant pleural effusions. Thorax 2000; 55:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/33\">",
"      Sahn SA, Good JT Jr. Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988; 108:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/34\">",
"      Brown NE, Zamel N, Aberman A. Changes in pulmonary mechanics and gas exchange following thoracocentesis. Chest 1978; 74:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/35\">",
"      Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997; 10:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/36\">",
"      Mart&iacute;nez-Morag&oacute;n E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/37\">",
"      Rodr&iacute;guez-Panadero F, L&oacute;pez Mej&iacute;as J. Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/38\">",
"      Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data. Chest 2000; 117:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/39\">",
"      Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/40\">",
"      Yoshida K, Sugiura T, Takifuji N, et al. Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 2007; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/41\">",
"      Balassoulis G, Sichletidis L, Spyratos D, et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol 2008; 31:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/42\">",
"      Caglayan B, Torun E, Turan D, et al. Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Ann Surg Oncol 2008; 15:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/43\">",
"      Salomaa ER, Pulkki K, Helenius H. Pleurodesis with doxycycline or Corynebacterium parvum in malignant pleural effusion. Acta Oncol 1995; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/44\">",
"      Terra RM, Kim SY, Pego-Fernandes PM, et al. Is silver nitrate pleurodesis for patients with malignant pleural effusion feasible and safe when performed in an outpatient setting? Ann Surg Oncol 2011; 18:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/45\">",
"      Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004; :CD002916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/46\">",
"      Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized comparison of thoracoscopic talc poudrage under local anesthesia versus bleomycin instillation for pleurodesis in malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/47\">",
"      American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000; 162:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/48\">",
"      Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 2005; 127:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/49\">",
"      Heffner JE, Standerfer RJ, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis. Chest 1994; 105:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/50\">",
"      Paschoalini Mda S, Vargas FS, Marchi E, et al. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 2005; 128:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/51\">",
"      Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy. Respirology 2006; 11:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/52\">",
"      Olivares-Torres CA, Laniado-Labor&iacute;n R, Ch&aacute;vez-Garc&iacute;a C, et al. Iodopovidone pleurodesis for recurrent pleural effusions. Chest 2002; 122:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/53\">",
"      Kennedy L, Rusch VW, Strange C, et al. Pleurodesis using talc slurry. Chest 1994; 106:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/54\">",
"      Xie C, Teixeira LR, McGovern JP, Light RW. Systemic corticosteroids decrease the effectiveness of talc pleurodesis. Am J Respir Crit Care Med 1998; 157:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/55\">",
"      Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial. World J Surg 2004; 28:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/56\">",
"      Villanueva AG, Gray AW Jr, Shahian DM, et al. Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions. Thorax 1994; 49:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/57\">",
"      Yildirim E, Dural K, Yazkan R, et al. Rapid pleurodesis in symptomatic malignant pleural effusion. Eur J Cardiothorac Surg 2005; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/58\">",
"      Spiegler PA, Hurewitz AN, Groth ML. Rapid pleurodesis for malignant pleural effusions. Chest 2003; 123:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/59\">",
"      Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax 2003; 58 Suppl 2:ii29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/60\">",
"      Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/61\">",
"      Porcel JM, Salud A, Nabal M, et al. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions. Support Care Cancer 2006; 14:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/62\">",
"      Sherman S, Ravikrishnan KP, Patel AS, Seidman JC. Optimum anesthesia with intrapleural lidocaine during chemical pleurodesis with tetracycline. Chest 1988; 93:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/63\">",
"      DiBardino DJ, Vanatta JM, Fagan SP, Awad SS. Acute respiratory failure after pleurodesis with doxycycline. Ann Thorac Surg 2002; 74:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/64\">",
"      Lorch DG, Gordon L, Wooten S, et al. Effect of patient positioning on distribution of tetracycline in the pleural space during pleurodesis. Chest 1988; 93:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/65\">",
"      Dryzer SR, Allen ML, Strange C, Sahn SA. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 1993; 104:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/66\">",
"      Goodman A, Davies CW. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial. Lung Cancer 2006; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/67\">",
"      Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size. Am J Respir Crit Care Med 2004; 170:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/68\">",
"      Froudarakis ME, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006; 129:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/69\">",
"      Kennedy L, Sahn SA. Talc pleurodesis for the treatment of pneumothorax and pleural effusion. Chest 1994; 106:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/70\">",
"      Abraham G, Cherian JH, Gopalakrishnan TJ. Pyopneumothorax with bronchofleural fistula following tetracycline pleurodesis in a patient on CAPD. Perit Dial Int 1992; 12:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/71\">",
"      KNOWLES JH, GORLIN R, STOREY CF. Effects of pleural talc poudrage on pulmonary function. J Thorac Surg 1957; 34:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/72\">",
"      PAUL JS, BEATTIE EJ Jr, BLADES B. Lung function studies in poudrage treatment of recurrent spontaneous pneumothorax. J Thorac Surg 1951; 22:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/73\">",
"      Cardillo G, Carleo F, Carbone L, et al. Long-term lung function following videothoracoscopic talc poudrage for primary spontaneous recurrent pneumothorax. Eur J Cardiothorac Surg 2007; 31:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/74\">",
"      de Campos JR, Vargas FS, de Campos Werebe E, et al. Thoracoscopy talc poudrage : a 15-year experience. Chest 2001; 119:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/75\">",
"      Campos JR, Werebe EC, Vargas FS, et al. Respiratory failure due to insufflated talc. Lancet 1997; 349:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/76\">",
"      Kennedy L, Harley RA, Sahn SA, Strange C. Talc slurry pleurodesis. Pleural fluid and histologic analysis. Chest 1995; 107:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/77\">",
"      Montes JF, Ferrer J, Villarino MA, et al. Influence of talc dose on extrapleural talc dissemination after talc pleurodesis. Am J Respir Crit Care Med 2003; 168:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/78\">",
"      Kleinfeld M, Messite J, Kooyman O, Zaki MH. Mortality among talc miners and millers in New York State. Arch Environ Health 1967; 14:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/79\">",
"      Lange P, Mortensen J, Groth S. Lung function 22-35 years after treatment of idiopathic spontaneous pneumothorax with talc poudrage or simple drainage. Thorax 1988; 43:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36232/abstract/80\">",
"      A survey of the long-term effects of talc and kaolin pleurodesis. Research Committee of the British Thoracic Association and the Medical Research Council Pneumoconiosis Unit. Br J Dis Chest 1979; 73:285.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6695 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36232=[""].join("\n");
var outline_f35_24_36232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Malignant effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonmalignant effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CHOICE OF AGENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROCEDURE VIA TUBE THORACOSTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pleural drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Sclerosant agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Talc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Doxycycline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Empyema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lung volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dissemination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/62/4072?source=related_link\">",
"      Diagnosis and management of pleural causes of unexpandable lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/29/37334?source=related_link\">",
"      Management of refractory nonmalignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/57/30615?source=related_link\">",
"      Talc pleurodesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36233="Enoxaparin: Drug information";
var content_f35_24_36233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enoxaparin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/51/26421?source=see_link\">",
"    see \"Enoxaparin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/55/42872?source=see_link\">",
"    see \"Enoxaparin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lovenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Enoxaparin Injection;",
"     </li>",
"     <li>",
"      Lovenox&reg;;",
"     </li>",
"     <li>",
"      Lovenox&reg; HP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F165118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Low Molecular Weight Heparin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F165080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One mg of enoxaparin is equal to 100 units of anti-Xa activity (World Health Organization First International Low Molecular Weight Heparin Reference Standard).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      DVT prophylaxis:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     In morbidly obese patients (BMI &ge;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ), increasing the prophylactic dose by 30% may be appropriate for some indications (Nutescu, 2009). For bariatric surgery, dose increases may be &gt;30% based on clinical trial data. SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Abdominal surgery:",
"     </i>",
"     40 mg once daily, with initial dose given 2 hours prior to surgery; continue until risk of DVT has diminished (usually 7-10 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Hip replacement surgery:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Twice-daily dosing: 30 mg every 12 hours, with initial dose within 12-24 hours after surgery, and every 12 hours for at least 10 days or until risk of DVT has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation &ge;12 hours preoperatively",
"     <b>",
"      or",
"     </b>",
"     &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Once-daily dosing: 40 mg once daily, with initial dose within 9-15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of DVT has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation &ge;12 hours preoperatively",
"     <b>",
"      or",
"     </b>",
"     &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Knee replacement surgery:",
"     </i>",
"     30 mg every 12 hours, with initial dose within 12-24 hours after surgery, and every 12 hours for at least 10 days or until risk of DVT has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation &ge;12 hours preoperatively",
"     <b>",
"      or",
"     </b>",
"     &ge;12 hours postoperatively; extended duration of up to 35 days suggested (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Medical patients with severely-restricted mobility during acute illness:",
"     </i>",
"     40 mg once daily; continue until risk of DVT has diminished (usually 6-11 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Bariatric surgery (unlabeled use):",
"     </i>",
"     Roux-en-Y gastric bypass: Appropriate dosing strategies have not been clearly defined (Borkgren-Okonek, 2008; Scholten, 2002):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BMI &le;50 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     : 40 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     BMI &gt;50 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     : 60 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Bariatric surgery guidelines suggest initiation 30-120 minutes before surgery and postoperatively until patient is fully mobile (Mechanick, 2009). Alternatively, limiting administration to the postoperative period may reduce perioperative bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Prevention of recurrent venous thromboembolism in pregnancy (unlabeled use):",
"     </i>",
"     40 mg once daily. Therapy should continue for 6 weeks postpartum in high-risk women (Bates, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      DVT treatment (acute):",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Start warfarin on the first or second treatment day and continue enoxaparin until INR is &ge;2 for at least 24 hours (usually 5-7 days) (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inpatient treatment (with or without pulmonary embolism):",
"     </i>",
"     1 mg/kg/dose every 12 hours or 1.5 mg/kg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Outpatient treatment (without pulmonary embolism):",
"     </i>",
"     1 mg/kg/dose every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     Use actual body weight to calculate dose; dose capping not recommended; use of twice daily dosing preferred (Nutescu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pregnant women:",
"     </i>",
"     1 mg/kg/dose every 12 hours. Discontinue &ge;24 hours prior to the induction of labor or cesarean section. Enoxaparin therapy may be substituted with heparin near term. Continue anticoagulation therapy for &ge;6 weeks postpartum (minimum duration of therapy: 3 months). LMWH or heparin therapy is preferred over warfarin during pregnancy (Bates, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Percutaneous coronary intervention (PCI), adjunctive therapy (unlabeled dosing):",
"     </b>",
"     I.V.: In patients treated with multiple doses of enoxaparin undergoing PCI, if PCI occurs within 8 hours after the last SubQ enoxaparin dose, no additional dosing is needed. If PCI occurs 8-12 hours after the last SubQ enoxaparin dose or the patient received only 1 therapeutic SubQ dose (eg, 1 mg/kg), a single I.V. dose of 0.3 mg/kg should be administered. If PCI occurs &gt;12 hours after the last SubQ dose, it is prudent to use an established anticoagulation regimen (eg, full-dose unfractionated heparin or bivalirudin) (Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      If patient has not received prior anticoagulant therapy:",
"     </i>",
"     0.5-0.75 mg/kg bolus dose (Levine, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ST-elevation MI (STEMI):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients &lt;75 years of age:",
"     </i>",
"     Initial: 30 mg I.V. single bolus plus 1 mg/kg (maximum 100 mg for the first 2 doses only) SubQ every 12 hours. The first SubQ dose should be administered with the I.V. bolus. Maintenance: After first 2 doses, administer 1 mg/kg SubQ every 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients &ge;75 years of age:",
"     </i>",
"     Initial: SubQ: 0.75 mg/kg every 12 hours (",
"     <b>",
"      Note:",
"     </b>",
"     No I.V. bolus is administered in this population); a maximum dose of 75 mg is recommended for the first 2 doses. Maintenance: After first 2 doses, administer 0.75 mg/kg SubQ every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     Use weight-based dosing; a maximum dose of 100 mg is recommended for the first 2 doses (Nutescu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Additional notes on STEMI treatment:",
"     </b>",
"     Therapy was continued for 8 days or until hospital discharge; optimal duration not defined. Unless contraindicated, all patients received aspirin (75-325 mg daily) in clinical trials. In patients with STEMI receiving thrombolytics, initiate enoxaparin dosing between 15 minutes before and 30 minutes after fibrinolytic therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Unstable angina or non-ST-elevation MI (NSTEMI):",
"     </b>",
"     1 mg/kg every 12 hours in conjunction with oral aspirin therapy (100-325 mg once daily); continue until clinical stabilization (a minimum of at least 2 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Obesity:",
"     </i>",
"     Use actual body weight to calculate dose; dose capping not recommended (Nutescu, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Conversion from I.V. unfractionated heparin (UFH) infusion to SubQ enoxaparin (Nutescu, 2007):",
"     </i>",
"     Calculate specific dose for enoxaparin based on indication, discontinue UFH and begin enoxaparin within 1 hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Conversion from SubQ enoxaparin to I.V. UFH infusion (Nutescu, 2007):",
"     </i>",
"     Discontinue enoxaparin, calculate specific dose for I.V. UFH infusion based on indication, omit heparin bolus/loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Converting from SubQ enoxaparin dosed every 12 hours: Start I.V. UFH infusion 10-11 hours after last dose of enoxaparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Converting from SubQ enoxaparin dosed every 24 hours: Start I.V. UFH infusion 22-23 hours after last dose of enoxaparin",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F165099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/55/42872?source=see_link\">",
"      see \"Enoxaparin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One mg of enoxaparin is equal to 100 units of anti-Xa activity (World Health Organization First International Low Molecular Weight Heparin Reference Standard).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Thromboembolism (unlabeled use; Monagle, 2012):",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Infants &lt;2 months:",
"     </i>",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: 0.75 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 1.5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Infants &gt;2 months and Children &le;18 years:",
"     </i>",
"     Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: 0.5 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 1 mg/kg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance: See",
"     <b>",
"      Dosage Titration",
"     </b>",
"     table:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Enoxaparin Pediatric Dosage Titration",
"      <sup>",
"       1",
"      </sup>",
"     </caption>",
"     <col align=\"left\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"185\">",
"     </col>",
"     <col align=\"center\" width=\"180\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Anti-Xa Result",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose Titration",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Time to Repeat Anti-Xa",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Measurement",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Nomogram to be used for treatment dosing.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Modified from Duplaga BA, et al, &ldquo;Dosing and Monitoring of Low-Molecular-Weight Heparins in Special Populations,&rdquo;",
"         <i>",
"          Pharmacotherapy",
"         </i>",
"         , 2001, 21(2):218-34.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;0.35 units/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Increase dose by 25%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after next dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0.35-0.49 units/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Increase dose by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after next dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         0.5-1 unit/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Keep same dosage",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Next day, then 1 wk later, then monthly (4 h after dose)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1.1-1.5 units/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease dose by 20%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Before next dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1.6-2 units/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold dose for 3 h and decrease dose by 30%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Before next dose, then 4 h after next dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;2 units/mL",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold all doses until anti-Xa is 0.5 units/mL, then decrease dose by 40%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Before next dose and every 12 h until anti-Xa &lt;0.5 units/mL",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F165081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     SubQ: Refer to adult dosing. Increased incidence of bleeding with doses of 1.5 mg/kg/day or 1 mg/kg every 12 hours; injection-associated bleeding and serious adverse reactions are also increased in the elderly. Careful attention should be paid to elderly patients, particularly those &lt;45 kg.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage alteration/adjustment may be required.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F165082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No specific adjustment recommended (per manufacturer); monitor closely for bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DVT prophylaxis in abdominal surgery, hip replacement, knee replacement, or in medical patients during acute illness: SubQ: 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DVT treatment (inpatient or outpatient treatment in conjunction with warfarin): SubQ: 1 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     STEMI:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;75 years: Initial: I.V.: 30 mg as a single dose with the first dose of the SubQ maintenance regimen administered at the same time as the I.V. bolus; Maintenance: SubQ: 1 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;75 years of age: Omit I.V. bolus; Maintenance: SubQ: 1 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unstable angina, NSTEMI: SubQ: 1 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Enoxaparin has not been FDA approved for use in dialysis patients. It's elimination is primarily via the renal route. Serious bleeding complications have been reported with use in patients who are dialysis dependent or have severe renal failure. LMWH administration at fixed doses without monitoring has greater unpredictable anticoagulant effects in patients with chronic kidney disease. If used, dosages should be reduced and anti-Xa levels frequently monitored, as accumulation may occur with repeated doses. Many clinicians would not use enoxaparin in this population especially without timely anti-Xa levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Supplemental dose is not necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F165050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium: 100 mg/mL (3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lovenox&reg;: 100 mg/mL (3 mL) [contains benzyl alcohol; vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [preservative free]: 30 mg/0.3 mL (0.3 mL); 40 mg/0.4 mL (0.4 mL); 60 mg/0.6 mL (0.6 mL); 80 mg/0.8 mL (0.8 mL); 100 mg/mL (1 mL); 120 mg/0.8 mL (0.8 mL); 150 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lovenox&reg;: 30 mg/0.3 mL (0.3 mL); 40 mg/0.4 mL (0.4 mL); 60 mg/0.6 mL (0.6 mL); 80 mg/0.8 mL (0.8 mL); 100 mg/mL (1 mL); 120 mg/0.8 mL (0.8 mL); 150 mg/mL (1 mL) [prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F165035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F165054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Enoxaparin is available in 100 mg/mL and 150 mg/mL concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SubQ: Administer by deep SubQ injection alternating between the left or right anterolateral and left or right posterolateral abdominal wall. Do not mix with other infusions or injections.  In order to minimize bruising, do not rub injection site. To avoid loss of drug from the 30 mg and 40 mg prefilled syringes, do not expel the air bubble from the syringe prior to injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: STEMI and PCI only: The manufacturer recommends using the multiple-dose vial to prepare I.V. doses. Do not mix or coadminister with other medications; may be administered with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W. Flush I.V. access site with a sufficient amount of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W prior to and following I.V. bolus administration. When used prior to percutaneous coronary intervention or as part of treatment for ST-elevation myocardial infarction (STEMI), a single dose may be administered I.V. except when the patient is &ge;75 years of age and is experiencing STEMI then only administer by SubQ injection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F165124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS; do not mix with other injections or infusions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F165053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute coronary syndromes: Unstable angina (UA), non-ST-elevation (NSTEMI), and ST-elevation myocardial infarction (STEMI)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     DVT prophylaxis: Following hip or knee replacement surgery, abdominal surgery, or in medical patients with severely-restricted mobility during acute illness who are at risk for thromboembolic complications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients at risk of thromboembolic complications who undergo abdominal surgery include those with one or more of the following risk factors: &gt;40 years of age, obesity, general anesthesia lasting &gt;30 minutes, malignancy, history of deep vein thrombosis or pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     DVT treatment (acute): Inpatient treatment (patients with or without pulmonary embolism) and outpatient treatment (patients without pulmonary embolism)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F165114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of thromboembolism in children; anticoagulant bridge therapy during temporary interruption of vitamin K antagonist therapy in patients at high risk for thromboembolism; DVT prophylaxis following moderate-risk general surgery, major gynecologic surgery and  following higher-risk general surgery for cancer; management of venous thromboembolism (VTE) during pregnancy; anticoagulant used during percutaneous coronary intervention (PCI)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F165126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Lovenox&reg; may be confused with Lasix&reg;, Levaquin&reg;, Lotronex&reg;, Protonix&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      National Patient Safety Goals:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F165116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all anticoagulants, bleeding is the major adverse effect of enoxaparin. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables. At the recommended doses, single injections of enoxaparin do not significantly influence platelet aggregation or affect global clotting time (ie, PT or aPTT).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (5% to 8%), confusion (2%), pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Bruising",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage (major, &lt;1% to 4%; includes cases of intracranial, retroperitoneal, or intraocular hemorrhage; incidence varies with indication/population), thrombocytopenia (moderate 1%; severe 0.1% - see \"",
"     <b>",
"      Note",
"     </b>",
"     \" below), anemia (&lt;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased (6%), AST increased (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site hematoma (9%), local reactions (irritation, pain, ecchymosis, erythema)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactic reaction, anaphylactoid reaction, cutaneous vasculitis (hypersensitive), eczematous plaques, hematoma (see note on \"Spinal or epidural hematomas\" below), hyperkalemia, hyperlipidemia (very rare), hypertriglyceridemia, intracranial hemorrhage (up to 0.8%), erythematous pruritic patches, pruritus, purpura, retroperitoneal bleeding, skin necrosis, thrombocytopenia with thrombosis, thrombocytosis, urticaria, vesicobullous rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spinal or epidural hematomas: Can occur following neuraxial anesthesia or spinal puncture, resulting in paralysis. Risk is increased in patients with indwelling epidural catheters or concomitant use of other drugs affecting hemostasis. Prosthetic valve thrombosis, including fatal cases, has been reported in pregnant women receiving enoxaparin as thromboprophylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombocytopenia with thrombosis: Cases of heparin-induced thrombocytopenia (some complicated by organ infarction, limb ischemia, or death) have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F165057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to enoxaparin, heparin, pork products, or any component of the formulation (including benzyl alcohol in multiple-dose vials); thrombocytopenia associated with a positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies in the presence of enoxaparin; active major bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of enoxaparin in patients with current heparin-induced thrombocytopenia (HIT) or HIT with thrombosis is",
"     <b>",
"      not",
"     </b>",
"     recommended and considered contraindicated due to high cross-reactivity to heparin-platelet factor-4 antibody (Guyatt [ACCP], 2012; Warkentin, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F165039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Monitor patient closely for signs or symptoms of bleeding. Certain patients are at increased risk of bleeding. Risk factors include bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; severe uncontrolled hypertension; history of hemorrhagic stroke; or use shortly after brain, spinal, or ophthalmic surgery; in patients treated concomitantly with platelet inhibitors; recent GI bleeding; thrombocytopenia or platelet defects; severe liver disease; hypertensive or diabetic retinopathy; or in patients undergoing invasive procedures. Discontinue if bleeding occurs. To minimize risk of bleeding following PCI, achieve hemostasis at the puncture site after PCI. If a closure device is used, sheath can be removed immediately. If manual compression is used, remove sheath 6 hours after the last I.V./SubQ dose of enoxaparin. Do not administer further doses until 6-8 hours after sheath removal; observe for signs of bleeding/hematoma formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Monitor for hyperkalemia; can cause hyperkalemia possibly by suppressing aldosterone production. Most commonly occurs in patients with risk factors for the development of hyperkalemia (eg, renal dysfunction, concomitant use of potassium-sparing diuretics or potassium supplements, hematoma in body tissues).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Cases of enoxaparin-induced thrombocytopenia and thrombosis (similar to heparin-induced thrombocytopenia [HIT]), some complicated by organ infarction, limb ischemia, or death, have been observed. Use with extreme caution or avoid in patients with history of HIT, especially if administered within 100 days of HIT episode (Warkentin, 2001); monitor platelet count closely. Use is contraindicated in patients with thrombocytopenia associated with a positive",
"     <i>",
"      in vitro",
"     </i>",
"     test for antiplatelet antibodies in the presence of enoxaparin. Discontinue therapy and consider alternative treatment if platelets are &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or thrombosis develops. Use caution in patients with congenital or drug-induced thrombocytopenia or platelet defects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prosthetic heart valves: Cannot be recommended for long-term thromboprophylaxis in patients with prosthetic heart valves (especially pregnant women) due to insufficient evidence.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure; dosage adjustment needed if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; delayed elimination may occur. Dosage alteration/adjustment may be required (eg, omission of I.V. bolus in acute STEMI in patients &ge;75 years of age).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Low weight patients: Risk of bleeding may be increased in women &lt;45 kg and in men &lt;57 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: There is no consensus for adjusting/correcting the weight-based dosage of LMWH for patients who are morbidly obese (BMI &ge;40 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Anti-Xa levels are increased to appropriate levels when enoxaparin is dosed on actual body weight in obese patients weighing up to 144 kg (Sanderink, 2002). Monitoring of anti-Xa levels 4 hours after the dose may be warranted. The American College of Chest Physicians Practice Guidelines suggest consulting with a pharmacist regarding dosing in bariatric surgery patients and other obese patients who may require higher doses of LMWH (Gould, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multidose vials: Contain benzyl alcohol and should not be used in pregnant women. In neonates, large amounts of benzyl alcohol (&gt;100 mg/kg/day) have been associated with fatal toxicity (gasping syndrome). Use of multiple-dose vials is contraindicated in patients who have hypersensitivity to benzyl alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Do",
"     <b>",
"      not",
"     </b>",
"     administer intramuscularly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Surgical patients: Discontinue use 12-24 hours prior to CABG and dose with unfractionated heparin per institutional practice (Jneid, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conversion to other products: Not to be used interchangeably (unit for unit) with heparin or any other low molecular weight heparins.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuraxial anesthesia:",
"     <b>",
"      [U.S. Boxed Warning]: Spinal or epidural hematomas, including subsequent paralysis, may occur with recent or anticipated neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients anticoagulated with LMWH or heparinoids. Consider risk versus benefit prior to spinal procedures; risk is increased by the use of concomitant agents which may alter hemostasis, the use of indwelling epidural catheters for analgesia, a history of spinal deformity or spinal surgery, as well as a history of traumatic or repeated epidural or spinal punctures. Patient should be observed closely for bleeding and signs and symptoms of neurological impairment if therapy is administered during or immediately following diagnostic lumbar puncture, epidural anesthesia, or spinal anesthesia.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F165044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Heparin (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Heparin (Low Molecular Weight) may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Potential benefits of therapeutic doses of LMW heparins should be weighed against an increased risk of bleeding in patients who receive drotrecogin alfa.  In patients receiving prophylactic LMW heparin doses consider continuing this during drotrecogin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palifermin: Heparin (Low Molecular Weight) may increase the serum concentration of Palifermin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Heparin (Low Molecular Weight).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F165071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid cat's claw, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, red clover, horse chestnut, green tea, ginseng (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F165046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F165060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Low molecular weight heparin (LMWH) does not cross the placenta; increased risks of fetal bleeding or teratogenic effects have not been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     LMWH is recommended over unfractionated heparin for the treatment of acute venous thromboembolism (VTE) in pregnant women. LMWH is also recommended over unfractionated heparin for VTE prophylaxis in pregnant women with certain risk factors (eg, homozygous factor V Leiden, antiphospholipid antibody syndrome with &ge;3 previous pregnancy losses). Prophylaxis is not routinely recommended for women undergoing assisted reproduction therapy; however, LMWH therapy is recommended for women who develop severe ovarian hyperstimulation syndrome. LMWH should be discontinued at least 24 hours prior to induction of labor or a planned cesarean delivery. For women undergoing cesarean section and who have additional risk factors for developing VTE, the prophylactic use of LMWH may be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     LMWH may also be used in women with mechanical heart valves (consult current ACCP guidelines for details). Women who require long-term anticoagulation with warfarin and who are considering pregnancy, LMWH substitution should be done prior to conception when possible. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt, 2012). Monitoring antifactor Xa levels is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Multiple-dose vials contain benzyl alcohol (avoid in pregnant women due to association with gasping syndrome in premature infants); use of preservative-free formulations is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F165085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F165061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of LMWH have been detected in breast milk; however, because it has a low oral bioavailability, it is unlikely to cause adverse events in a nursing infant. Enoxaparin product labeling does not recommend use in nursing women; however, antithrombotic guidelines state that use of LMWH may be continued in breast-feeding women (Guyatt, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F165059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Enoxaparin Sodium Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/3 mL (3 mL): $253.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Enoxaparin Sodium Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/0.3 mL (0.3 mL): $19.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/0.4 mL (0.4 mL): $26.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/0.6 mL (0.6 mL): $39.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/0.8 mL (0.8 mL): $65.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (1 mL): $81.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg/0.8 mL (0.8 mL): $97.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/mL (1 mL): $121.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lovenox Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg/3 mL (3 mL): $297.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Lovenox Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/0.3 mL (0.3 mL): $29.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg/0.4 mL (0.4 mL): $39.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg/0.6 mL (0.6 mL): $59.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/0.8 mL (0.8 mL): $79.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (1 mL): $99.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg/0.8 mL (0.8 mL): $119.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg/mL (1 mL): $149.07",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F165048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelets, occult blood, anti-Xa levels, serum creatinine; monitoring of PT and/or aPTT is not necessary. Routine monitoring of anti-Xa levels is not required, but has been utilized in patients with obesity and/or renal insufficiency. Monitoring anti-Xa levels is recommended in pregnant women receiving therapeutic doses of enoxaparin or when receiving enoxaparin for the prevention of thromboembolism with mechanical heart valves (Guyatt, 2012). For patients &gt;190 kg, if anti-Xa monitoring is available, adjusting dose based on anti-Xa levels is recommended; if anti-Xa monitoring is unavailable, reduce dose if bleeding occurs (Nutescu, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6823430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following therapeutic ranges for anti-Xa levels have been suggested, but have not been validated in a controlled trial. Anti-Xa level measured 4 hours postdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of venous thromboembolism: Anti-Xa concentration target (Garcia, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Once-daily dosing:",
"     </i>",
"     &gt;1 anti-Xa units/mL; the manufacturer recommends a range of 1-2 anti-Xa units/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Twice-daily dosing:",
"     </i>",
"     0.6-1 anti-Xa units/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recurrent VTE prophylaxis in pregnant women: Peak anti-Xa concentrations: 0.2-0.6 units/mL (Bates, 2012)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F165062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Clenox (CO, PE);",
"     </li>",
"     <li>",
"      Clexa (PH);",
"     </li>",
"     <li>",
"      Clexane (AR, AU, BB, BE, BF, BG, BJ, BM, BR, BS, CH, CI, CL, CN, CO, CR, CZ, DE, DO, EC, EE, ES, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, IE, IL, IN, IT, JM, KE, KP, LR, LU, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NZ, PA, PE, PH, PK, PL, PR, PY, RU, SC, SD, SG, SL, SN, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Clexane Forte (AU, IL, SG);",
"     </li>",
"     <li>",
"      Decipar (ES);",
"     </li>",
"     <li>",
"      Klexane (DK, FI, NO, SE);",
"     </li>",
"     <li>",
"      Lomoh-40 (PH);",
"     </li>",
"     <li>",
"      Lomoh-60 (PH);",
"     </li>",
"     <li>",
"      Lovenox (AT, FR, ID, PT);",
"     </li>",
"     <li>",
"      Microparin (DO, GT, SV);",
"     </li>",
"     <li>",
"      Plaucina (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F165038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Standard heparin consists of components with molecular weights ranging from 4000-30,000 daltons with a mean of 16,000 daltons. Heparin acts as an anticoagulant by enhancing the inhibition rate of clotting proteases by antithrombin III impairing normal hemostasis and inhibition of factor Xa. Low molecular weight heparins have a small effect on the activated partial thromboplastin time and strongly inhibit factor Xa. Enoxaparin is derived from porcine heparin that undergoes benzylation followed by alkaline depolymerization. The average molecular weight of enoxaparin is 4500 daltons which is distributed as (&le;20%) 2000 daltons (&ge;68%) 2000-8000 daltons, and (&le;15%) &gt;8000 daltons. Enoxaparin has a higher ratio of antifactor Xa to antifactor IIa activity than unfractionated heparin.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F165056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: SubQ: Antifactor Xa and antithrombin (antifactor IIa): 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 40 mg dose: Antifactor Xa activity: ~12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 4.3 L (based on antifactor Xa activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Does not bind to heparin binding proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, to lower molecular weight fragments (little activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, plasma: 2-4 times longer than standard heparin, independent of dose; based on anti-Xa activity: 4.5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40% of dose; 10% as active fragments)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al,&ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Cohen M, Radley D, et al, &ldquo;Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non-Q-Wave Myocardial Infarction. TIMI 11B-ESSENCE Meta-analysis,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(15):1602-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/10517730/pubmed\" id=\"10517730\" target=\"_blank\">",
"        10517730",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, McCabe CH, Gurfinkel EP, et al, &ldquo;Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non-Q-Wave Myocardial Infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(15):1593-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/10517729/pubmed\" id=\"10517729\" target=\"_blank\">",
"        10517729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Morrow DA, McCabe CH, et al, &ldquo;Enoxaparin Versus Unfractionated Heparin With Fibrinolysis for ST-Elevation Myocardial Infarction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(14):1477-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/16537665/pubmed\" id=\"16537665\" target=\"_blank\">",
"        16537665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bates SM, Greer IA, Middeldorp S, et al. &ldquo;VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e691-736.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22315276/pubmed\" id=\"22315276\" target=\"_blank\">",
"        22315276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borkgren-Okonek MJ, Hart RW, Pantano JE, et al, &ldquo;Enoxaparin Thromboprophylaxis in Gastric Bypass Patients: Extended Duration, Dose Stratification, and Antifactor Xa Activity,&rdquo;",
"      <i>",
"       Surg Obes Relat Dis",
"      </i>",
"      , 2008, 4(5):625-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/18261965/pubmed\" id=\"18261965\" target=\"_blank\">",
"        18261965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen M, Bigonzi F, Le Louer V, et al, &ldquo;One Year Follow-Up of the ESSENCE Trial (Enoxaparin Versus Heparin in Unstable Angina and Non-Q Wave Myocardial Infarction),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1998, 31:79A.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen M, Demers C, Gurfinkel EP, et al, &ldquo;A Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin for Unstable Coronary Artery Disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(7):447-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/9250846/pubmed\" id=\"9250846\" target=\"_blank\">",
"        9250846",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dumaine R, Borentain M, Bertel O, et al, &ldquo;Intravenous Low-Molecular Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2007, 167(22):2423-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/18071163/pubmed\" id=\"18071163\" target=\"_blank\">",
"        18071163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duplaga BA, Rivers CW, and Nutescu E, &ldquo;Dosing and Monitoring of Low-Molecular-Weight Heparins in Special Populations,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2001, 21(2):218-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/11213859/pubmed\" id=\"11213859\" target=\"_blank\">",
"        11213859",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Farooq V, Hegarty J, Chandrasekar T, et al, &ldquo;Serious Adverse Incidents With the Usage of Low Molecular Weight Heparins in Patients With Chronic Kidney Disease,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2004, 43(3):531-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/14981611/pubmed\" id=\"14981611\" target=\"_blank\">",
"        14981611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferguson JJ, Califf RM, Antman EM, et al, &ldquo;Enoxaparin vs. Unfractionated Heparin in High-Risk Patients With Non-ST-segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy: Primary Results of the SYNERGY Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 292(1):45-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/15238590/pubmed\" id=\"15238590\" target=\"_blank\">",
"        15238590",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KA, &ldquo;Low Molecular Weight Heparin (Enoxaparin) in the Management of Unstable Angina: The ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events,&rdquo;",
"      <i>",
"       Heart",
"      </i>",
"      , 1999, 82(Suppl 1):112-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/10377325/pubmed\" id=\"10377325\" target=\"_blank\">",
"        10377325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia DA, Baglin TP, Weitz JI, et al, &ldquo;Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):24-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22315264/pubmed\" id=\"22315264\" target=\"_blank\">",
"        22315264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerlach AT, Pickworth KK, Seth SK, et al, &ldquo;Enoxaparin and Bleeding Complications: A Review in Patients With and Without Renal Insufficiency,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2000, 20(7):771-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/10907967/pubmed\" id=\"10907967\" target=\"_blank\">",
"        10907967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MK, Garcia DA, Wren SM, et al, &ldquo;Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e227-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22315263/pubmed\" id=\"22315263\" target=\"_blank\">",
"        22315263",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaff MR, McMurtry MS, Archer SL, et al, &ldquo;Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(16):1788-830.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/21422387/pubmed\" id=\"21422387\" target=\"_blank\">",
"        21422387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al, &ldquo;Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association,&rdquo;",
"      <i>",
"       Stroke",
"      </i>",
"      , 2013, 44(3):870-947.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/23370205/pubmed\" id=\"23370205\" target=\"_blank\">",
"        23370205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner FG, Hand M, Smith SC, et al, &ldquo;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2205-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/19942100/pubmed\" id=\"19942100\" target=\"_blank\">",
"        19942100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mechanick JI, Kushner RF, Sugerman HJ, et al, &ldquo;American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic &amp; Bariatric Surgery Medical Guidelines for Clinical Practice for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient,&rdquo;",
"      <i>",
"       Obesity",
"      </i>",
"      , 2009, 17(Suppl 1):1-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/19319140/pubmed\" id=\"19319140\" target=\"_blank\">",
"        19319140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chan A, Goldenberg NA, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):e737-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/22315277/pubmed\" id=\"22315277\" target=\"_blank\">",
"        22315277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montalescot G, Philippe F, Ankri A, et al, &ldquo;Early Increase of von Willebrand Factor Predicts Adverse Outcome in Unstable Coronary Artery Disease: Beneficial Effects of Enoxaparin. French Investigators of the ESSENCE Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(4):294-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/9711933/pubmed\" id=\"9711933\" target=\"_blank\">",
"        9711933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nagge J, Crowther M, and Hirsh J, &ldquo;Is Impaired Renal Function a Contraindication to the Use of Low-Molecular Weight Heparin?&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2002, 162(22):2605-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/12456233/pubmed\" id=\"12456233\" target=\"_blank\">",
"        12456233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nutescu EA and Dager W, &ldquo;Heparin, Low Molecular Weight Heparin, and Fondaparinux,&rdquo;",
"      <i>",
"       Managing Anticoagulation Patients in the Hospital",
"      </i>",
"      , Gulseth M ed, American Society of Health-System Pharmacists&reg;, Bethesda, MD: 2007, 181.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nutescu EA, Spinler SA, Wittkowsky A, et al, &ldquo;Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2009, 43(6):1064-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/19458109/pubmed\" id=\"19458109\" target=\"_blank\">",
"        19458109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polkinghorne KR, McMahon LP, and Becker GJ, &ldquo;Pharmacokinetic Studies of Dalteparin (Fragmin), Enoxaparin (Clexane), and Danaparoid Sodium (Orgaran) in Stable Chronic Hemodialysis Patients,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 40(5):990-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/12407644/pubmed\" id=\"12407644\" target=\"_blank\">",
"        12407644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reach L, Debure A, de Groc F, et al, &ldquo;Anticoagulation With Enoxaparin 0.5 mg/kg in 630 Dialysis Sessions,&rdquo;",
"      <i>",
"       Haemostasis",
"      </i>",
"      , 1994, 24(Suppl 1):280 [abstract 281]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanderink GJ, Le Liboux A, Jariwala N, et al, &ldquo;The Pharmacokinetic and Pharmacodynamics of Enoxaparin in Obese Volunteers,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 2002, 72(3):308-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/12235452/pubmed\" id=\"12235452\" target=\"_blank\">",
"        12235452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scholten DJ, Hoedema RM, and Scholten SE, &ldquo;A Comparison of Two Different Prophylactic Dose Regimens of Low Molecular Weight Heparin in Bariatric Surgery,&rdquo;",
"      <i>",
"       Obes Surg",
"      </i>",
"      , 2002, 12(1):19-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/11868291/pubmed\" id=\"11868291\" target=\"_blank\">",
"        11868291",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simonneau G, Charbonnier B, Decousus H, et al, &ldquo;Subcutaneous Low-Molecular-Weight Heparin Compared With Continuous Intravenous Unfractionated Heparin in the Treatment of Proximal Deep Vein Thrombosis,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(13):1541-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/8391792/pubmed\" id=\"8391792\" target=\"_blank\">",
"        8391792",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Von Visger J and Magee C, &ldquo;Low Molecular Weight Heparins in Renal Failure,&rdquo;",
"      <i>",
"       J Nephrol",
"      </i>",
"      , 2003, 16(6):914-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/14736021/pubmed\" id=\"14736021\" target=\"_blank\">",
"        14736021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wallentin L, Goldstein P, Armstrong PW, et al, &ldquo;Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2003, 108(2): 135-42.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE and Barkin RL, &ldquo;Newer Strategies for the Treatment of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(2):181-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/10030768/pubmed\" id=\"10030768\" target=\"_blank\">",
"        10030768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Warkentin TE and Kelton JG, &ldquo;Temporal Aspects of Heparin-Induced Thrombocytopenia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(17):1286-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/11320387/pubmed\" id=\"11320387\" target=\"_blank\">",
"        11320387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong GC, Giugliano RP, and Antman EM, &ldquo;Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289:331-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/12525234/pubmed\" id=\"12525234\" target=\"_blank\">",
"        12525234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zed PJ, Tisdale JE, and Borzak S, &ldquo;Low-Molecular-Weight Heparins in the Management of Acute Coronary Syndromes,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1999, 159(16):1849-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/24/36233/abstract-text/10493315/pubmed\" id=\"10493315\" target=\"_blank\">",
"        10493315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9407 Version 53.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36233=[""].join("\n");
var outline_f35_24_36233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708731\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165076\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165077\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165118\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165080\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165099\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165081\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165082\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822424\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165050\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165054\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165124\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165053\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165114\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165126\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165116\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165057\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165039\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299264\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165044\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165071\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165046\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165060\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165085\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165061\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165059\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165048\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6823430\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165062\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165038\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165056\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/51/26421?source=related_link\">",
"      Enoxaparin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/55/42872?source=related_link\">",
"      Enoxaparin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36234="Selecting antiretroviral regimens for the treatment naive HIV-infected patient";
var content_f35_24_36234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36234/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36234/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/24/36234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/24/36234/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/24/36234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of human immunodeficiency virus (HIV) infection has been revolutionized by potent antiretroviral therapy (ART). Use of these multidrug regimens has resulted in substantial reductions in progression to AIDS, opportunistic infections, hospitalizations, and deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug selection is becoming increasingly complex, with more than 20 antiretroviral medications available in six major classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This topic will address the goals of therapy, the various drug classes, and the efficacy of different regimens for initial treatment.",
"   </p>",
"   <p>",
"    Indications for initiating antiretroviral therapy in treatment-naive patients, appropriate patient evaluation prior to initiation of therapy, individual patient considerations (including counseling about adverse effects) prior to starting therapy, and laboratory monitoring are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the HIV-infected woman during pregnancy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOALS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When ART is administered, the following goals are desired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Durable suppression of HIV viral load to less than 50",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"     </li>",
"     <li>",
"      Restoration of immune function (as indicated by the CD4 cell count)",
"     </li>",
"     <li>",
"      Prevention of HIV transmission",
"     </li>",
"     <li>",
"      Prevention of drug resistance",
"     </li>",
"     <li>",
"      Improvement in quality of life",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UNDERSTANDING COMBINATION ANTIRETROVIRAL REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regimens are described as having a \"backbone\" and a \"base\". The backbone typically consists of two nucleoside reverse transcriptase inhibitors (NRTIs). The base has traditionally included either a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor (PI). In December 2009,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , from the integrase inhibitor class, was also added to the list of potent antiretroviral medications recommended by the DHHS Guidelines for initial treatment of the HIV-infected patient in combination with a backbone of two NRTIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/5\">",
"     5",
"    </a>",
"    ]. The International AIDS Society-USA Panel also made a similar recommendation in July 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiretroviral therapy (ART) regimens should have at least three active antiretroviral medications. Activity against HIV is determined by drug resistance testing prior to initiation of therapy; however, these tests will not detect resistant HIV in low concentrations. Detailed information regarding drug resistance testing and interpretation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, regimens with four active drugs are not recommended since they are not more efficacious than three-drug regimens in treatment-naive patients and are associated with more adverse events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In addition, regimens composed of three classes of drugs are no more potent than regimens comprised of two different classes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/8\">",
"     8",
"    </a>",
"    ]. In general, three-drug regimens that include three drugs from the same class (ie, nucleoside analogs) are not as effective as regimens that combine drugs from different classes and are not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33682?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H40\">",
"     'Antiretroviral combinations to avoid'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antiretroviral classifications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Drug classes used in treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classes of antiretroviral drugs used in initial regimens include (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"mobipreview.htm?24/25/24989\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nucleoside (and nucleotide) reverse transcriptase inhibitors (NRTIs)",
"     </li>",
"     <li>",
"      Non-nucleoside reverse transcriptase inhibitors (NNRTIs)",
"     </li>",
"     <li>",
"      Protease inhibitors (PIs)",
"     </li>",
"     <li>",
"      Integrase strand transfer inhibitors (INSTIs)",
"     </li>",
"     <li>",
"      CCR5 antagonists",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , a CCR5 antagonist for treatment-naive patients, in November 2009 based on a trial that showed that maraviroc plus two NRTIs was noninferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    plus two NRTIs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/9\">",
"     9",
"    </a>",
"    ]. Maraviroc is considered an &ldquo;alternative&rdquo; choice for treatment-naive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'NNRTI-based ART versus CCR5-based ART'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Drug classes not used in treatment-naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusion inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/2/7205?source=see_link\">",
"     enfuvirtide",
"    </a>",
"    ) are not approved for treatment-naive patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abbreviations used",
"    </span>",
"    &nbsp;&mdash;&nbsp;The table shows the abbreviations for medications used in this topic (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"mobipreview.htm?24/25/24989\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pharmacokinetic boosting with ritonavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a PI is selected, pharmacokinetic boosting with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is standard and preferred, whenever possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     Ritonavir",
"    </a>",
"    is a potent inhibitor of hepatic microsomal enzyme CYP (450) 3A4. This characteristic is used to \"boost\" the serum concentration of other protease inhibitors. Use of pharmacokinetic boosting improves trough serum concentrations and rates of viral suppression; use of ritonavir also enables lower dosing of the parent drug, thereby decreasing pill burden (",
"    <a class=\"graphic graphic_table graphicRef81007 \" href=\"mobipreview.htm?6/19/6460\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At doses of 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is not counted as an active individual agent in any ART regimen; in this dose range, it is only a \"pharmacologic enhancer.\" Full-dose ritonavir (600 mg twice daily) is virtually never used to treat HIV due to significant adverse effects at this dose.",
"   </p>",
"   <p>",
"    The major drawbacks of using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    boosting are related to an increased risk of gastrointestinal intolerance, hyperlipidemia, and drug interactions. All of these adverse effects are dose related. Pharmacokinetic boosting is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link&amp;anchor=H32#H32\">",
"     \"HIV protease inhibitors\", section on 'Pharmacokinetic boosting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Provider expertise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs now used have brought a host of new concerns including expense, side effects, drug interactions, and emergence of drug resistance.",
"   </p>",
"   <p>",
"    The management of ART is complex and should be delivered by providers with specific training. Multiple older studies showed that provider experience correlates with better patient outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The potential magnitude of this effect was illustrated in a study of 403 HIV-infected men diagnosed between 1984 and 1994 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/10\">",
"     10",
"    </a>",
"    ]. After controlling for disease severity and year of diagnosis, patients of physicians with the most clinical experience (based on HIV clinic panel size) had a 31 percent reduction in the risk of death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EFFICACY BY DRUG CLASS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general statement, non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase inhibitor-based regimens are all considered effective for initial HIV therapy, although advantages and disadvantages differ [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NNRTIs have been the major comparator in most large treatment efficacy trials during the last several years. The discussion below is divided into two parts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      NNRTIs versus PI-based antiretroviral therapy (ART)",
"     </li>",
"     <li>",
"      NNRTIs versus integrase inhibitor-based ART",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    NNRTIs have also been compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    -based ART for the initial treatment of HIV-infected patients. However, as noted above, there are limited clinical data upon which to recommend a CCR5 antagonist (ie, maraviroc) at present for the treatment-naive patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ]. At present, maraviroc is considered an &ldquo;alternative&rdquo; agent for the treatment-naive patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An overview of the use of various classes of antiretroviral agents is given below. More specific data on the individual agents themselves is given later in this topic within the specific sections on the various drug classes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     NNRTI-based ART versus PI-based ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparative trials have demonstrated that regimens based on NNRTIs or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs, with a backbone of two nucleoside reverse transcriptase inhibitors (NRTIs), are nearly comparable for initial treatment of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Most of these trials have utilized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    as the NNRTI agent because of its overall potency, toxicity profile and convenient dosing, compared with other NNRTI agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Non-nucleoside reverse transcriptase inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A meta-analysis of 12 comparative trials in antiretroviral-naive patients found that NNRTI-based therapy is associated with similar rates of death and disease progression as with PI-based ART [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/13\">",
"     13",
"    </a>",
"    ]. Similar findings were noted in a subsequent randomized trial in 1397 treatment-naive patients with a five-year follow-up: PI and NNRTI-based strategies were equivalent in clinical efficacy and immunologic outcomes, although viral suppression to &lt;50",
"    <span class=\"nowrap\">",
"     copies/microL",
"    </span>",
"    was achieved more rapidly in the NNRTI arm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14774?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The AIDS Clinical Trial Group (ACTG) 5142 trial also demonstrated significantly better virologic responses with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based regimen compared with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    -based regimen at 96 weeks (89 versus 77 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/14\">",
"     14",
"    </a>",
"    ]. However, better CD4 cell count responses and less drug resistance were noted in the boosted PI arm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14774?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues regarding drug resistance and adverse events profiles that should be considered in drug selection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug resistance to most PIs requires multiple mutations and seldom develops after a first regimen failure with boosted PI-based regimens. In contrast, resistance to both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      is conferred by a single mutation (eg, K103N).",
"     </li>",
"     <li>",
"      One study of 7891 patients demonstrated that the cumulative risk of drug resistance by eight years of therapy was 28 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the probability of developing drug resistance was lower in patients who initiated PI-based ART compared with those who initiated NNRTI-based ART (adjusted relative hazard, 0.35; 95% CI 0.26-0.50).",
"     </li>",
"     <li>",
"      Some PIs are associated with gastrointestinal intolerance and metabolic disturbances, whereas",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      use is associated with more rash and central nervous system side effects. These side effects usually abate within approximately two to three weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preferred and alternative agents within the PI and NNRTI classes are discussed within the specific sections below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     NNRTI-based ART versus INSTI-based ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is the only drug available within the integrase inhibitor class for use in combination ART with two NRTIs. Two trials suggest that raltegravir is effective first-line therapy in treatment-naive patients when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based ART, although the experience with raltegravir as initial therapy is less extensive than efavirenz and many boosted PI-based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The STARTMRK trial compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , each in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/16\">",
"     16",
"    </a>",
"    ]. At 48 weeks of follow-up, the patients in the raltegravir arm had similar rates of viral suppression (&lt;50",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    as those in the efavirenz group (86 versus 82 percent). The results at 96 weeks also showed comparable rates of viral suppression, although the raltegravir recipients had a greater CD4 cell count increase and fewer adverse reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -based ART as initial treatment are the limited data on durability, the need for twice daily dosing, and its low genetic barrier to resistance (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    ). The advantages of raltegravir are better overall tolerance and limited potential for drug interactions. Some experts prefer to use raltegravir in patients with multidrug-resistant virus rather than for initial therapy in the treatment-naive patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     NNRTI-based ART versus CCR5-based ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    , a CCR5 antagonist, has also been compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in treatment-na&iuml;ve patients. A post-hoc analysis found that maraviroc was noninferior to efavirenz in virologic efficacy when both were combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (ie, Combivir) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In this trial the rate of adverse reactions requiring treatment discontinuation was greater in the efavirenz recipients (16 percent versus 6 percent), while the rate of virologic failure was greater in the maraviroc recipients (13 versus 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. These data are discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: CCR5 antagonists\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/45/20182?source=see_link\">",
"     Maraviroc",
"    </a>",
"    appears to be well tolerated. However, concerns remain regarding the high cost of the screening tropism assay (nearly $2000), which is needed to determine treatment eligibility with a CCR5 antagonist. Maraviroc also requires twice-daily dosing. Larger trials with longer follow-up will also be needed to assess efficacy and long-term safety and potency in the treatment-naive patient. Clinicians should also note that maraviroc has only been studied in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians can consider an NNRTI, PI, or integrase inhibitor-based regimen in combination with dual NRTIs for initial HIV therapy. CCR5 inhibitors are not currently recommended for the treatment-naive patient pending the availability of further published data.",
"   </p>",
"   <p>",
"    The particular choice of agents may depend on side effect profiles, comorbidities, potential drug interactions, results of resistance testing, allergy history, pregnancy status, or patient convenience. Preferred agents within the individual classes are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROTEASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease inhibitors (PIs) are potent antiretroviral agents, which have the advantage of having a relatively high genetic barrier to resistance compared with non-nucleoside reverse transcriptase inhibitors (NNRTIs) and integrase inhibitors; the development of resistance to protease inhibitors in previously antiretroviral-na&iuml;ve individuals is uncommon even with less than optimal adherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Preferred agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"     Lopinavir-ritonavir",
"    </a>",
"    was considered a preferred agent within the PI class for several years. However, increasing concerns about adverse events associated with lopinavir-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    including metabolic effects (eg, hypertriglyceridemia), cardiovascular events (eg, myocardial infarction), and significant gastrointestinal toxicity led to a renewed focus on alternative PI agents.",
"   </p>",
"   <p>",
"    In 2009, the Department of Health and Human Services (DHHS) panel selected",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    as preferred agents within the PI class because of their overall efficacy, dosing convenience, and side effect profiles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/5\">",
"     5",
"    </a>",
"    ]. In 2010, the IAS-USA guidelines also recognized boosted atazanavir and darunavir as preferred options within the PI class; however, the IAS-USA guidelines also acknowledge that some clinicians may defer the use of boosted darunavir in treatment-naive patient populations because of its efficacy in patients with multidrug-resistant virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    have shown greater antiviral efficacy than boosted lopinavir with long-term follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CASTLE trial compared once-daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      with twice-daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      , each in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/21\">",
"       21",
"      </a>",
"      ]. Atazanavir-ritonavir was superior to lopinavir-ritonavir with respect to viral suppression (74 percent versus 66 percent) at 96 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similarly designed trial (ARTEMIS) demonstrated that patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      achieved significantly higher rates of viral suppression than with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      at 96 weeks (79 versus 72 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    also have the advantage of requiring only 100 mg daily of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    compared with 200 mg of ritonavir when given with lopinavir. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, the ACTG 5142 trial demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based antiretroviral therapy (ART) was virologically superior to boosted lopinavir. However, the observation that boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    -based regimens were both virologically superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    has raised questions as to whether efavirenz-based ART is virologically superior to all PI regimens. To date, there are no comparative trials of efavirenz versus atazanavir or darunavir-based ART. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'NNRTI-based ART versus INSTI-based ART'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Adverse events and dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Atazanavir (Reyataz)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two US Food and Drug Administration (FDA)-approved dosing regimens are: a)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    400 mg (two 200 mg capsules) once a day unboosted, and b) atazanavir 300 mg (one 300 mg capsule) once a day plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    100 mg once a day (ie, boosted atazanavir). The 2011 DHHS guidelines and the 2010 IAS-USA guidelines recommend \"boosted\" atazanavir as a \"preferred\" PI for na&iuml;ve patients; unboosted atazanavir is listed in the \"alternative\" category [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This agent has the advantages of better gastrointestinal tolerance than most other PIs, once-daily dosing, and good potency.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    is not associated with the development of insulin resistance, as compared with other agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    . Lipid profiles show mild increases in cholesterol and triglycerides that are mainly related to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disadvantages include the need for gastric acid and food for optimal absorption; thus concomitant use of drugs that alter stomach pH (eg, proton pump inhibitors) may impair absorption of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    . Atazanavir can also lead to an increase in the indirect serum bilirubin concentration, which is benign, but may cause jaundice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Darunavir (Prezista)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    for treatment-na&iuml;ve patients is 800 mg once daily (given as two 400 mg tablets) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    (100 mg) once daily.",
"   </p>",
"   <p>",
"    The principle adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    include nausea, diarrhea, increased transaminases, hepatotoxicity, headache and rash, including Stevens-Johnson syndrome. Some patients who developed rash also had fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transaminase elevations. Darunavir contains a sulfonamide moiety and should be used with caution in patients with a known sulfonamide allergy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative PI agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    , or lopinavir. These agents are classified as alternative PI agents because of issues related to potency, toxicity, or convenience. Both the IAS-USA and DHHS guidelines specifically recommend against using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    because of concerns regarding QT-interval prolongation announced by the FDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Requirements for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    dosing for pharmacologic boosting have also been considered since ritonavir&rsquo;s associated side effects are dose related.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    only require 100 mg of ritonavir daily as compared with some protease inhibitors, which require higher concomitant dosing of ritonavir (eg, lopinavir,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The non-nucleoside reverse transcriptase inhibitors (NNRTIs) are potent agents, but have the limitation of a low genetic barrier to resistance;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    require only a single mutation to confer drug resistance. Furthermore, a major mutation (such as K103N) leads to cross-resistance to other members of the class with one exception.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    has in vitro activity against some viruses with mutations that confer resistance to the other NNRTIs in this class, but is used within salvage regimens for treatment-experienced patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/10/27816?source=see_link\">",
"     Delavirdine",
"    </a>",
"    is no longer used due to frequency of dosing and numerous associated drug interactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Preferred agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Efavirenz (Sustiva)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the NNRTIs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    is the preferred agent within this class because of its overall demonstrated potency, convenience, and toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    has been used extensively since 1998 and has the advantages of excellent potency, low pill burden, and durability in treatment-naive patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4,6,25-32\">",
"     4,6,25-32",
"    </a>",
"    ]. Efavirenz has demonstrated comparable virologic efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    -based ART; efavirenz has also demonstrated superior virologic activity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    has also been demonstrated among patients with high pretreatment viral loads and low CD4 cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The main problems with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Side effects: Central nervous system toxicity is common, although usually restricted to the first two to three weeks of initiation. Patients should be counseled regarding this side effect before initiating therapy. Higher rates of intolerance are noted in black patients due to delayed metabolism that is genetically determined. Some experts prefer other alternatives to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      in patients with a history of depression and persons with selected high-risk occupations (eg, airplane pilots).",
"     </li>",
"     <li>",
"      Teratogenic potential:",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      is the only class D antiretroviral agent and must be avoided in the first trimester of pregnancy or in women who may become pregnant.",
"     </li>",
"     <li>",
"      Potential for drug interactions, since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      is an inducer of cytochrome P450.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Alternative agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Nevirapine (Viramune)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one large randomized controlled trial comparing NNRTIs (2NN trial), there were no significant differences in virologic or immunologic outcomes among treatment-naive patients assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4,25\">",
"     4,25",
"    </a>",
"    ]. Nevirapine was also noninferior to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and lopinavir-containing ART in two trials that included patients with low CD4 cell counts",
"    <span class=\"nowrap\">",
"     (&lt;250/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    is more toxic during the first three months of therapy in the treatment-naive patient; complications have included hepatic necrosis and serious cutaneous reactions, including deaths due to hepatic necrosis or Stevens-Johnson Syndrome.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    is considered an &ldquo;acceptable&rdquo; alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    for the treatment of HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/36\">",
"     36",
"    </a>",
"    ]. However, nevirapine should",
"    <strong>",
"     NOT",
"    </strong>",
"    be initiated in women with a baseline CD4 count &gt;250",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    or in men with a CD4 count &gt;400",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    since these CD4 thresholds represent major risk factors for hepatotoxicity. Nevirapine is also a suitable choice when efavirenz use is contraindicated (eg, pregnancy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    , a dose of 200 mg once daily is prescribed for 14 days prior to increasing to the maintenance dose of 200 mg twice daily. Some experts recommend monitoring serum aminotransferases at baseline, prior to and two weeks after dose escalation, then monthly for the first three months. Patients should also be counseled about symptoms of hepatotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4006153\">",
"    <span class=\"h3\">",
"     Rilpivirine (Edurant)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two controlled trials (ECHO and THRIVE) compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    in treatment-naive patients in combination with two nucleoside reverse transcriptase inhibitors (NRTIs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The pooled results demonstrated that the proportion of patients with viral suppression at 48 weeks was comparable in the rilpivirine and efavirenz-containing arms. Rilpivirine was also well tolerated and associated with minimal changes in lipids.",
"   </p>",
"   <p>",
"    However, among those subjects with a baseline viral load &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    the risk of virologic failure was higher in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    arm compared with the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    arm. Virologic failure on rilpivirine may also compromise the anti-HIV activity of other NNRTIs, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     etravirine",
"    </a>",
"    , which may be useful for patients with HIV multi-drug resistance. An increased risk of nucleoside analog resistance mutations (eg,",
"    <span class=\"nowrap\">",
"     M184V/I)",
"    </span>",
"    was also noted in these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link&amp;anchor=H658623#H658623\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\", section on 'Efavirenz versus rilpivirine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link&amp;anchor=H29#H29\">",
"     \"Primer on interpretation of HIV drug resistance testing\", section on 'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    should be considered as an alternative agent and should only be used in treatment-na&iuml;ve patients with a baseline viral load less than 100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     INTEGRASE STRAND TRANSFER INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371202\">",
"    <span class=\"h2\">",
"     Preferred agent",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    was shown to be comparable to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    with respect to viral suppression in a double-blind non-inferiority trial in treatment-na&iuml;ve patients over 192 weeks of follow-up. Raltegravir is noted for its overall excellent tolerance and its lack of impact on lipids. One of its main disadvantages is the need for twice-daily dosing (ie, 400 mg twice daily). Clinicians should note that this agent has been studied only in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    as an NRTI backbone. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    also has a low genetic barrier to resistance; N155H is its signature mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    in pregnancy is currently under evaluation. Clinicians are advised to report instances of prenatal exposure to antiretroviral therapy drugs to the Antiretroviral Pregnancy Registry at",
"    <a class=\"external\" href=\"file://www.apregistry.com/\">",
"     www.APRegistry.com",
"    </a>",
"    ; Telephone 1-800-258-4263. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24037?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Entry and integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371264\">",
"    <span class=\"h2\">",
"     Alternative agent",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H371084\">",
"    <span class=\"h3\">",
"     Elvitegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two phase 3 randomized clinical studies of 1408 treatment-naive patients, elvitegravir, coformulated with cobicistat (a pharmacokinetic enhancer),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    was noninferior to coformulated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -emtricitabine-tenofovir and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    in achieving viral suppression at 48 weeks of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The most common adverse events on the elvitegravir regimen were diarrhea, nausea and headache; four patients on elvitegravir in the phase 3 clinical trials developed proximal tubulopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link&amp;anchor=H1981991#H1981991\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\", section on 'Elvitegravir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The coformulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/54/8041?source=see_link\">",
"     elvitegravir-cobicistat-tenofovir-emtricitabine",
"    </a>",
"    (Stribild) was approved by the US Food and Drug Administration (FDA) for once-daily use in treatment-naive patients with a pre-treatment creatinine clearance of greater than 70",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Clinicians should be aware that elvitegravir is metabolized through CYP3A enzymes; thus, drug-drug interactions must be thoroughly assessed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/56/11144?source=see_link\">",
"     \"Pharmacology of integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     NUCLEOSIDE ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleoside analogs, or nucleoside reverse transcriptase inhibitors (NRTIs), are considered the \"backbone\" of antiretroviral therapy (ART) and are generally used in combination with a non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), or integrase inhibitor. NRTIs are usually given in pairs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ; and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and lamivudine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. All of these combinations are available as coformulations; Truvada (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    ), Combivir (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    ) and Epzicom (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    ), respectively. Coformulations enable decreased pill burden and possibly improve patient adherence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Preferred agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Department of Health and Human Services (DHHS) guidelines panel recommends",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    as the preferred nucleoside analog coformulation in combination ART for the treatment-naive patient because of its overall potency, favorable toxicity profile, and convenience of dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Tenofovir-emtricitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;An open-label, noninferiority trial was performed among 517 treatment-naive patients who were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    , both in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/27\">",
"     27",
"    </a>",
"    ]. Viral suppression rates were significantly higher among patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (84 versus 73 percent, respectively). Also, through 144 weeks of follow-up, significantly more patients in the tenofovir-emtricitabine arm reached and maintained viral suppression than in the zidovudine-lamivudine arm (71 versus 58 percent) with significantly less lipoatrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/43\">",
"     43",
"    </a>",
"    ]. The emergence of the signature mutation for lamivudine-emtricitabine resistance (M184V) was also less common in patients assigned to tenofovir-emtricitabine than to those assigned to zidovudine-lamivudine. Furthermore, the signature mutation of tenofovir (K65R) did not emerge in any patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     Tenofovir-emtricitabine",
"    </a>",
"    is also the preferred agent for HIV-infected patients with concomitant hepatitis B virus infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=see_link\">",
"     \"Treatment of hepatitis B in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal impairment, characterized by increases in serum creatinine, glycosuria, hypophosphatemia, and acute tubular necrosis has been reported in association with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/45\">",
"     45",
"    </a>",
"    ]. Risk factors include advanced HIV infection, diabetes, and hypertension. Tenofovir should be avoided in patients with a baseline creatinine clearance of &lt;50",
"    <span class=\"nowrap\">",
"     cc/mL",
"    </span>",
"    and renal function should be monitored during use of this agent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     Tenofovir-emtricitabine",
"    </a>",
"    is given as a single tablet daily with or without regard to food.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Alternative agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DHHS guidelines recommend either Epzicom (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    ) or Combivir (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    ) as alternative nucleoside analog backbones for combination ART.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Abacavir-lamivudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pendulum has swung back and forth with respect to the use of Epzicom as the nucleoside analog backbone of ART.",
"   </p>",
"   <p>",
"    The use of Epzicom (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    ) gained favor in 2007 when the risk of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    -associated hypersensitivity reaction (fever, rash, and abnormal aminotransferases) was largely eliminated by screening for the genetic marker HLA-B*5701 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/46\">",
"     46",
"    </a>",
"    ]. At that time, Epzicom was considered to be comparable to Truvada in terms of virologic efficacy and toxicity profile in two non-inferiority trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    is now considered an alternative agent by the DHHS guidelines panel because of concerns regarding its virologic potency, particularly among those with high-level viremia (&gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], and because of its possible contribution to cardiovascular disease risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virologic failure &mdash; In a randomized, blinded equivalence trial (ACTG 5202) involving 1858 eligible patients, four once-daily ART regimens were compared in treatment-naive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/49\">",
"       49",
"      </a>",
"      ]. These regimens included",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"       abacavir-lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      Among the 797 patients with screening plasma HIV RNA levels of &ge;100,000",
"      <span class=\"nowrap\">",
"       copies/mL,",
"      </span>",
"      there were twice as many virologic failures among those treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      compared with those assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      at a median follow-up of 60 weeks. No differences were seen with respect to CD4 cell count changes at week 48. These results have raised concerns about potency, although other prospective and retrospective studies of smaller size or without blinding have not confirmed these findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/47,52\">",
"       47,52",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Abacavir should also not be dispensed with tenofovir. Virologic failure occurred in approximately half of the study patients participating in a clinical trial of abacavir-tenofovir-lamivudine combination therapy in treatment-naive patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/53\">",
"       53",
"      </a>",
"      ]. In a follow-up pharmacodynamic study, abacavir plus tenofovir did not have additive antiviral activity, despite adequate intracellular drug concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/54\">",
"       54",
"      </a>",
"      ]. The mechanism for these observations is unclear, but the combination of abacavir and tenofovir, with or without lamivudine, is not recommended as a nucleoside analog backbone for HIV treatment.",
"     </li>",
"     <li>",
"      Cardiovascular events &mdash; Prospective data from the D:A:D trial and the ACTG 5202 trial and a retrospective analysis of the SMART data suggested that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      may be associated with an increase risk of hyperlipidemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/49\">",
"       49",
"      </a>",
"      ] and cardiovascular events. However, subsequent studies have found no association or only a weak association between abacavir and the risk for myocardial infarction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]. To date, there is no consensus on whether there is a true association between abacavir and the risk of myocardial infarction, nor on a possible mechanistic explanation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link\">",
"       \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Summary &mdash; Use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      should be limited to persons who have a negative HLA-B*5701 screening test. Pending further data, abacavir-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      should not be administered to persons with significant risk factors for coronary artery disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"       \"Considerations prior to initiating antiretroviral therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=see_link\">",
"       \"Abacavir hypersensitivity reaction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=see_link\">",
"       \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Combivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coformulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    (ie, Combivir) was a preferred choice when it was first introduced in 1997, but is now considered an acceptable alternative regimen to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (ie, Truvada; preferred NRTI backbone) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    (ie, Epzicom; alternative NRTI backbone) for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combivir requires twice-daily dosing whereas Truvada or Epzicom are dosed once daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      is associated with gastrointestinal intolerance, fatigue, lactic acidosis, anemia and loss of limb fat [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/44,59\">",
"       44,59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combivir has been shown to have inferior virologic potency compared to Truvada-based ART [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/27,44\">",
"       27,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SELECTING A REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groups such as the International AIDS Society-USA Panel (IAS-USA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ] and the US Department of Health and Human Services (DHHS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ] have published guidelines for initial antiretroviral therapy (ART) based on data from randomized controlled trials, which demonstrate potency based on surrogate endpoints, such as viral suppression and improvements in CD4 cell counts. A summary of the DHHS guidelines is found below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     DHHS guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 DHHS guidelines indicate preference for the following regimens for initial treatment selected on the basis of demonstrated potency in clinical trials, relatively low frequency of serious adverse reactions, substantial clinical experience, and dosing frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A non-nucleoside reverse transcriptase inhibitor (NNRTI),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , plus two nucleoside reverse transcriptase inhibitors (NRTIs)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A boosted protease inhibitor (PI):",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      once daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      -ritonavir once daily plus two NRTIs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OR",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An integrase inhibitor,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      (400 mg twice daily) with two NRTIs.",
"     </li>",
"     <li>",
"      The recommended NRTI coformulation is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      in all of the above combinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered to women who may become pregnant or during the first trimester of pregnancy (see below). For more detailed information on these regimens, see",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_tables.pdf\">",
"     table 6 of the DHHS Antiretroviral Guidelines for Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Other options",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on individual patient characteristics and needs, an alternative regimen may actually be a preferred regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ]. Alternatives to the above recommendations are included for use in selected patients (",
"    <a class=\"graphic graphic_table graphicRef82655 \" href=\"mobipreview.htm?19/52/20301\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70143 \" href=\"mobipreview.htm?31/0/31757\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     IAS-USA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 IAS-USA guidelines are generally in agreement with the DHHS guidelines noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ]. For example, the IAS-USA guidelines also recommend fixed-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    as the preferred NRTI backbone for combination ART, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    as an alternative choice if HLA-B*5701 testing is negative.",
"   </p>",
"   <p>",
"    Although the panel generally supported the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    -ritonavir or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    as a potential third agent for treatment-naive patients, the members noted that more clinical data are available for the use of efavirenz and boosted atazanavir in treatment-naive patients than for the other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"     4",
"    </a>",
"    ].The panel also noted that many HIV experts consider darunavir or raltegravir as less attractive options for initial therapy because these two agents have an important role in the treatment of patients with multidrug-resistant virus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     ANTIRETROVIRAL COMBINATIONS TO AVOID",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain combinations of antiretroviral medications should be avoided either because of toxicity, lack of efficacy, or drug antagonism. Clinicians need to always check for potential drug interactions before prescribing an antiretroviral therapy (ART) regimen (",
"    <a class=\"graphic graphic_table graphicRef69670 \" href=\"mobipreview.htm?24/56/25487\">",
"     table 5",
"    </a>",
"    ). For more detailed information on drug interactions,",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_tables.pdf\">",
"     see tables 8, 9, and 16b of the DHHS Antiretroviral Guidelines for Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     NRTI combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleoside reverse transcriptase inhibitor (NRTI) combinations to avoid include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      : This combination has pharmacologic and in vivo antagonism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      : This combination should not be used since these individual agents are essentially identical drugs with the same primary resistance mutation (ie, M184V). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"       \"Primer on interpretation of HIV drug resistance testing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      : Didanosine should not be used in combination with stavudine due to overlapping mitochondrial toxicities such as peripheral neuropathy and lipodystrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"      is no longer recommended for the initial treatment of HIV-infected patients due to toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       Didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      : This combination is not recommended due to high rates of virologic failure, blunted CD4 T-cell responses, and rapid selection of resistant mutants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/64-69\">",
"       64-69",
"      </a>",
"      ]. The use of this combination may also lead to increased concentrations of didanosine, which can lead to lactic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"       \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      : Insufficient data",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Triple nucleoside analog combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, three-drug regimens that include three drugs from the same class (ie, nucleoside analogs) are not as effective as regimens that combine drugs from different classes and are not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/53,70,71\">",
"     53,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Non-nucleoside reverse transcriptase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    together produces more side effects and is less efficacious than either drug alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ) is not recommended because of efficacy concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    should not be used in patients with baseline HIV RNA levels &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    due to the risk of virologic failure and drug resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    has not been studied in large randomized clinical trials in treatment-naive patients and is thus not recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/62/19433?source=see_link\">",
"     Nelfinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    (boosted or unboosted) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    are no longer recommended by any guideline for initial treatment of HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Double protease inhibitor (PI) combinations are not routinely recommended for initial HIV therapy. These combinations are often associated with significant lipid abnormalities.",
"   </p>",
"   <p>",
"    A combination of unboosted",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is not recommended because of efficacy concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/24/36234/abstract/3,72\">",
"     3,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Illustrative examples",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate initial antiretroviral therapy (ART) regimens can be constructed using the above guidelines. For more detailed information on these regimens, see",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_tables.pdf\">",
"     table 7 of the DHHS Antiretroviral Guidelines for Adults and Adolescents",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The following are examples of such regimens that may be appropriate in many patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       Efavirenz",
"      </a>",
"      600 mg daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (300",
"      <span class=\"nowrap\">",
"       mg/200",
"      </span>",
"      mg) daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above regimen, coformulated as Atripla, requires only one pill taken once daily.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    should not be used in women who are pregnant or are likely to become pregnant. The patient must be warned of the central nervous system (CNS) side effects that are frequently noted in the initial few days after dosing. Many recommend that efavirenz be taken initially on an empty stomach since food promotes absorption and the CNS complications are dose related. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential PI-based regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      (800",
"      <span class=\"nowrap\">",
"       mg/100",
"      </span>",
"      mg) once daily with food plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"       abacavir-lamivudine",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/300",
"      </span>",
"      mg) daily. This regimen might be preferred in the patient who is chronically taking proton pump inhibitors (PPIs) since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      has significant drug interactions with PPIs.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       Atazanavir",
"      </a>",
"      300 mg daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      100 mg daily with food plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (300",
"      <span class=\"nowrap\">",
"       mg/200",
"      </span>",
"      mg) daily or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"       abacavir-lamivudine",
"      </a>",
"      (600",
"      <span class=\"nowrap\">",
"       mg/300",
"      </span>",
"      mg) daily. This regimen may be preferred in the patient with a history of a sulfa allergy since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      should be avoided in this circumstance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another potential ART regimen includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    , an integrase inhibitor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      (400 mg twice daily) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is a particularly attractive option for patients with either abnormal lipid profiles or risk factors for coronary artery disease, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    has a neutral effect on cholesterol and triglycerides compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , which is associated with greater lipid abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Drug resistance testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baseline resistance needs to be included in decisions on agents selected for initial treatment. The major concern is the K103N and other mutations that confer complete resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    and can be seen in treatment-naive patients due to transmission of a resistant strain.",
"   </p>",
"   <p>",
"    This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     CONSIDERATIONS IN SELECTED CLINICAL SETTINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient considerations in choosing antiretroviral therapy (ART) also include issues regarding pregnancy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    treatment, substance abuse patterns, probability of adherence, and comorbidities such as hyperlipidemia, liver disease, heart disease, psychiatric conditions, and renal insufficiency. This is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=see_link\">",
"     \"Considerations prior to initiating antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=see_link\">",
"       \"Patient information: Starting treatment for HIV (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=see_link\">",
"       \"Patient information: HIV/AIDS (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/31/15861?source=see_link\">",
"       \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/56/2946?source=see_link\">",
"       \"Patient information: Tips for taking HIV medications (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/60/1986?source=see_link\">",
"       \"Patient information: Testing for HIV (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of antiretroviral therapy (ART) is viral suppression to &lt;50",
"      <span class=\"nowrap\">",
"       cells/mL;",
"      </span>",
"      secondary goals are immunologic restoration and prevention of HIV-related complications and prevention of adverse drug reactions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Goals of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ART regimens for treatment-na&iuml;ve patients are composed of a \"base\" and a \"backbone\". The base is either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). The backbone typically consists of two nucleoside reverse transcriptase inhibitors (NRTIs). Two and preferably three active drugs are desired when possible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Understanding combination antiretroviral regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four-drug regimens are no more effective than three-drug regimens and may be associated with greater toxicity. Two of the three drugs used in combination ART should be selected from different classes of agents to improve efficacy and decrease the risk of resistance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Understanding combination antiretroviral regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selected non-nucleoside reverse transcriptase inhibitor-, protease inhibitor-, or integrase inhibitor-based regimens are all considered comparable and effective for initial HIV therapy. The particular choice of agents may depend on side effect profiles, comorbidities, potential drug interactions, results of resistance testing, allergy history, pregnancy status, or patient convenience. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Efficacy by drug class'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       Ritonavir",
"      </a>",
"      -boosting of PIs is preferred because of increased serum concentrations which lead to greater efficacy and decreased rates of resistance. We recommend either boosted",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      as a first-line protease inhibitor, rather than boosted lopinavir (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Atazanavir and darunavir have superior efficacy and improved side effect profiles. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Protease inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      as the first-line NNRTI, rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Efavirenz has superior virologic efficacy, a more favorable toxicity profile, and offers the convenience of once-daily dosing. However, efavirenz should not be administered to women of child-bearing potential or who are pregnant; nevirapine is the preferred NNRTI agent in this situation. Caution is necessary in patients with major psychiatric conditions. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Non-nucleoside reverse transcriptase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      as a first-line nucleoside analog coformulation, rather than other nucleoside analog coformulations (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/56/901?source=see_link\">",
"       zidovudine-lamivudine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"       abacavir-lamivudine",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      has a more favorable toxicity profile and superior efficacy than the alternative agents. Baseline renal disease with a creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      is a contraindication to tenofovir. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Nucleoside analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/27/10678?source=see_link\">",
"       Raltegravir",
"      </a>",
"      is the only agent available within the integrase class. It is generally well-tolerated and does not adversely affect lipids. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Integrase strand transfer inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/4/3141?source=see_link\">",
"       Abacavir-lamivudine",
"      </a>",
"      (Epzicom) should only be administered if HLA-B*5701 screening for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      hypersensitivity is negative. This combination should be avoided in patients at high risk of coronary artery disease and should be used with caution if the patient's baseline HIV RNA level is &gt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Nucleoside analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain combinations of antiretroviral medications should be avoided either because of toxicity, lack of efficacy, or drug antagonism. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Antiretroviral combinations to avoid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/1\">",
"      Sterne JA, Hern&aacute;n MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/2\">",
"      Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009; 48:1335.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/4\">",
"      Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the DHHS Panel on Antiretroviral guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council, December 1, 2009. file://AIDSinfo.nih.gov. (Accessed on December 01, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/6\">",
"      Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/7\">",
"      Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 2010; 51:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/8\">",
"      MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/9\">",
"      Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/10\">",
"      Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/11\">",
"      Brosgart CL, Mitchell TF, Coleman RL, et al. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis 1999; 28:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/12\">",
"      Cunningham WE, Tisnado DM, Lui HH, et al. The effect of hospital experience on mortality among patients hospitalized with acquired immunodeficiency syndrome in California. Am J Med 1999; 107:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/13\">",
"      Chou R, Fu R, Huffman LH, Korthuis PT. Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 2006; 368:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/14\">",
"      Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/15\">",
"      UK Collaborative Group on HIV Drug Resistance, UK CHIC Study Group. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis 2010; 50:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/16\">",
"      Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796.",
"     </a>",
"    </li>",
"    <li>",
"     Lennox J, DeJesus E, Lazzarin A, et al. Raltegravir Demonstrates Durable Efficacy through 96 Weeks (Wk): Results from STARTMRK, A Phase III Study of Raltegravir (RAL)-based vs Efavirenz (EFV)-based Therapy in Treatment-Naive HIV+ Patients (Pts). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2009). San Francisco. September 12-15, 2009. Abstract H-924b.",
"    </li>",
"    <li>",
"     Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Abstract #WESS104.",
"    </li>",
"    <li>",
"     Su Z. 48th Annual ICAAC/IDSA 46th Annual Meeting. October 25-28, 2008, Washington, DC, Abstract H-895 and H-1232a.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/20\">",
"      Gardner EM, Hullsiek KH, Telzak EE, et al. Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS 2010; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/21\">",
"      Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/22\">",
"      Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/23\">",
"      Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 2010; 24:2019.",
"     </a>",
"    </li>",
"    <li>",
"     FDA report file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.htm (Accessed on July 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/25\">",
"      van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/26\">",
"      Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/27\">",
"      Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/28\">",
"      Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/29\">",
"      Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/30\">",
"      Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 2001; 15:1679.",
"     </a>",
"    </li>",
"    <li>",
"     Montaner JS, Saag MS, Barylski C, Siemon-Hryczyk P. FOCUS study: saquinavir QD reigmen versus efavirenz QD regimen 48 week analysis in HIV infected patients. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002; San Diego. (Abstract).",
"    </li>",
"    <li>",
"     Bartlett JA, Johnson J, Herrera G, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) preliminary 48 week results. In 14th International AIDS Conference; 2002; Barcelona. (Abstract).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/33\">",
"      Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 2008; 197:1006.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2010/Abstracts/39798.htm (Accessed on July 29, 2010).",
"    </li>",
"    <li>",
"     file://www.ias2009.org/pag/Abstracts.aspx?AID=3709 (Accessed on July 29, 2010).",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     Cohen C, et al. XVIIIth International AIDS Conference, Vienna, Austria, 18-23 July 2010. Abstract THLBB206 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/38\">",
"      Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/39\">",
"      Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229.",
"     </a>",
"    </li>",
"    <li>",
"     file://aidsinfo.nih.gov/contentfiles/NNRTI_One_Page_Info-RPV.pdf (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/41\">",
"      DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/42\">",
"      Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/43\">",
"      Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008; 47:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/44\">",
"      Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/45\">",
"      Zimmermann AE, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/46\">",
"      Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/47\">",
"      Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/48\">",
"      DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/49\">",
"      Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/50\">",
"      Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.retroconference.org/2010/Abstracts/39789.htm (Accessed on July 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/52\">",
"      Bansi L, Sabin C, Gilson R, et al. Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis 2009; 200:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/53\">",
"      Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/54\">",
"      Goicoechea M, Jain S, Bi L, et al. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients. AIDS 2010; 24:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/55\">",
"      Durand M, Sheehy O, Baril JG, et al. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Qu&eacute;bec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/56\">",
"      Choi AI, Vittinghoff E, Deeks SG, et al. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/57\">",
"      Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/58\">",
"      Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011; 52:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/59\">",
"      Berenguer J, Gonz&aacute;lez J, Ribera E, et al. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 2008; 47:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/60\">",
"      Havlir DV, Tierney C, Friedland GH, et al. In vivo antagonism with zidovudine plus stavudine combination therapy. J Infect Dis 2000; 182:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/61\">",
"      Falc&oacute; V, Rodr&iacute;guez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002; 34:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/62\">",
"      C&ocirc;t&eacute; HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/63\">",
"      Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/64\">",
"      Maitland D, Moyle G, Hand J, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005; 19:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/65\">",
"      Le&oacute;n A, Mallolas J, Martinez E, et al. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir. AIDS 2005; 19:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/66\">",
"      Barrios A, Rend&oacute;n A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS 2005; 19:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/67\">",
"      Lacombe K, Pacanowski J, Meynard JL, et al. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. AIDS 2005; 19:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/68\">",
"      Negredo E, Bonjoch A, Paredes R, et al. Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies. Clin Infect Dis 2005; 41:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/69\">",
"      Annan NT, Nelson M, Mandalia S, et al. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr 2009; 51:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/24/36234/abstract/70\">",
"      Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850.",
"     </a>",
"    </li>",
"    <li>",
"     Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: The Tonus study.11th Conference on Retroviruses and Opportunstic Infections, February 2004, San Francisco.",
"    </li>",
"    <li>",
"     Campbell T, Smeaton L, De Grutolla V, et al. PEARLS (ACTG A5175): a multinational study of didanosine, emtricitabine, and atazanavir vs. co-formulated zidovudine/lamivudine and efavirenz for initial treatment of HIV infection. Presented at the 17th International AIDS conference 2008; Mexico City, Mexico. Abstract THAB0404.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3773 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-D141E0F7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36234=[""].join("\n");
var outline_f35_24_36234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H50\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOALS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UNDERSTANDING COMBINATION ANTIRETROVIRAL REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antiretroviral classifications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Drug classes used in treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Drug classes not used in treatment-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abbreviations used",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pharmacokinetic boosting with ritonavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Provider expertise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EFFICACY BY DRUG CLASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NNRTI-based ART versus PI-based ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NNRTI-based ART versus INSTI-based ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NNRTI-based ART versus CCR5-based ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROTEASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Preferred agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Atazanavir (Reyataz)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Darunavir (Prezista)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Preferred agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Efavirenz (Sustiva)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Nevirapine (Viramune)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4006153\">",
"      - Rilpivirine (Edurant)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      INTEGRASE STRAND TRANSFER INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371202\">",
"      Preferred agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H371264\">",
"      Alternative agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H371084\">",
"      - Elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      NUCLEOSIDE ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Preferred agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Tenofovir-emtricitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Alternative agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Abacavir-lamivudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Combivir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SELECTING A REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      DHHS guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Other options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      IAS-USA guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      ANTIRETROVIRAL COMBINATIONS TO AVOID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      NRTI combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Triple nucleoside analog combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Illustrative examples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      CONSIDERATIONS IN SELECTED CLINICAL SETTINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/25/24989\" title=\"table 1\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/19/6460\" title=\"table 2\">",
"      RTV boosted PI regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/52/20301\" title=\"table 3\">",
"      Acceptable regimens for ART-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/0/31757\" title=\"table 4\">",
"      Preferred and alternative regimens for ART-naive patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/56/25487\" title=\"table 5\">",
"      Drug interactions with PIs NNRTIs CCR5 antagonists",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24037?source=related_link\">",
"      Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32918?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/27/14774?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33682?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/18/3370?source=related_link\">",
"      Considerations prior to initiating antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/60/1986?source=related_link\">",
"      Patient information: Testing for HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/56/2946?source=related_link\">",
"      Patient information: Tips for taking HIV medications (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/56/11144?source=related_link\">",
"      Pharmacology of integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_24_36235="GENES mnemonic for identifying hereditary conditions";
var content_f35_24_36235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Academy of Family Physicians Family GENES mnemonic for identifying red flags for hereditary conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Features",
"      </td>",
"      <td class=\"subtitle1\">",
"       Examples",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        G",
"       </strong>",
"       roup of congenital anomalies",
"      </td>",
"      <td>",
"       While anatomic variation is normal, the presence of multiple variations may be indicative of a genetic syndrome.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        E",
"       </strong>",
"       xtreme or exceptional presentation of common conditions",
"      </td>",
"      <td>",
"       Examples of this include the onset of disease at a younger than average age, unusually severe presentation of illness, multiple primary cancers, recurrent miscarriages.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        N",
"       </strong>",
"       eurodevelopmental delay or degeneration",
"      </td>",
"      <td>",
"       Developmental delay or regression in children and early onset dementia in adults may be a sign of a genetic condition.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        E",
"       </strong>",
"       xtreme or exceptional pathology",
"      </td>",
"      <td>",
"       Some tumor pathologies may be suggestive of an inherited condition. Examples include medullary thyroid cancer, pheochromocytoma, plexiform neurofibromas, and multiple colon polyps.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        S",
"       </strong>",
"       urprising laboratory values",
"      </td>",
"      <td>",
"       Certain laboratory values may indicate an inherited defect in metabolic or clotting pathways. Examples include elevated fasting transferrin-iron saturation and cholesterol level &gt;500 mg/dL.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rich, EC, Burke, W, Heaton, CJ, et al. Reconsidering the family history in primary care. Journal of General Internal Medicine 2004; 19:273-280 and SCREEN: Taking a Family for Familial Disease. At American Academy of Family Physicians file://www.aafp.org. (Accessed July 30, 2007).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36235=[""].join("\n");
var outline_f35_24_36235=null;
var title_f35_24_36236="Cytochrome enzymes involv";
var content_f35_24_36236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticancer agents that are known substrates of cytochrome P450",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cytochrome P450 isoenzymes involved in metabolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Busulfan",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cisplatin",
"       </td>",
"       <td>",
"        2E1, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        2B6, 2C9, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytarabine",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dacarbazine",
"       </td>",
"       <td>",
"        1A1, 1A2, 2E1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Docetaxel",
"       </td>",
"       <td>",
"        1B1, 3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Doxorubicin",
"       </td>",
"       <td>",
"        2D6, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erlotinib",
"       </td>",
"       <td>",
"        1A1, 1A2, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etoposide",
"       </td>",
"       <td>",
"        1A2, 2E1, 3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gefitinib",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyurea",
"       </td>",
"       <td>",
"        Specific isoenzyme not reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idarubicin",
"       </td>",
"       <td>",
"        2D6, 2C9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ifosfamide",
"       </td>",
"       <td>",
"        2A6, 2B1, 2B6, 2C9, 2C18, 2C19, 3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imatinib",
"       </td>",
"       <td>",
"        1A2, 2C9, 2C19, 2D6, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irinotecan",
"       </td>",
"       <td>",
"        3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mitoxantrone",
"       </td>",
"       <td>",
"        Specific isoenzyme not reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paclitaxel",
"       </td>",
"       <td>",
"        2C8, 3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Procarbazine",
"       </td>",
"       <td>",
"        1A, 2B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tamoxifen",
"       </td>",
"       <td>",
"        1A1, 1A2, 1B1, 2B6, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Teniposide",
"       </td>",
"       <td>",
"        3A4, 3A5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topotecan",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toremifene",
"       </td>",
"       <td>",
"        1A2, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tretinoin",
"       </td>",
"       <td>",
"        2C8, 2C9, 2E, 3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinblastine",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vincristine",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vinorelbine",
"       </td>",
"       <td>",
"        3A4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Scripture CD, Spareboome A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncology 2005; 6:780.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36236=[""].join("\n");
var outline_f35_24_36236=null;
var title_f35_24_36237="Etiology aseptic meningitis";
var content_f35_24_36237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of aseptic meningitis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"15%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"28%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uncommon",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Infectious causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" rowspan=\"10\">",
"        Viruses",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Enteroviruses:",
"       </td>",
"       <td rowspan=\"10\">",
"        <p>",
"         Mumps",
"        </p>",
"        <p>",
"         HIV",
"        </p>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Respiratory viruses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Polioviruses",
"        </p>",
"        <p>",
"         Echoviruses",
"        </p>",
"        <p>",
"         Coxsackieviruses",
"        </p>",
"        <p>",
"         Numbered enteroviruses",
"        </p>",
"       </td>",
"       <td class=\"sublist1\">",
"        <p>",
"         Adenovirus",
"        </p>",
"        <p>",
"         Influenza",
"        </p>",
"        <p>",
"         Parainfluenza",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex virus type 2*",
"       </td>",
"       <td>",
"        Lymphocytic choriomeningitis virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arboviruses:",
"       </td>",
"       <td>",
"        Measles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"6\">",
"        <p>",
"         Eastern and Western equine encephalitis",
"        </p>",
"        <p>",
"         St. Louis encephalitis",
"        </p>",
"        <p>",
"         La Crosse (California) encephalitis",
"        </p>",
"        <p>",
"         West Nile",
"        </p>",
"       </td>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotavirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Herpes viruses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Herpes simplex virus type 1",
"        </p>",
"        <p>",
"         Human herpes virus 6",
"        </p>",
"        <p>",
"         Epstein-Barr virus",
"        </p>",
"        <p>",
"         Varicella zoster",
"        </p>",
"        <p>",
"         Cytomegalovirus",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Arboviruses:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         Powassan virus",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Bacteria",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Borrelia burgdorferi",
"         </em>",
"         (Lyme disease)*",
"        </p>",
"        <p>",
"         Partially treated bacterial meningitis*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Mycobacterium tuberculosis",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         Parameningeal infection (epidural, subdural abscess)*",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Bartonella",
"         </em>",
"         sp (cat scratch disease)*",
"        </p>",
"        <p>",
"         Syphilis*",
"        </p>",
"        <p>",
"         <em>",
"          Leptospira",
"         </em>",
"         sp*",
"        </p>",
"        <p>",
"         <em>",
"          Brucella",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         <em>",
"          Mycoplasma pneumoniae",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         <em>",
"          Rickettsia",
"         </em>",
"         *",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Fungi",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Cryptococcus",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         <em>",
"          Coccidioides",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         <em>",
"          Histoplasma",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         <em>",
"          Blastomyces",
"         </em>",
"         *",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Candida",
"         </em>",
"         spp*",
"        </p>",
"        <p>",
"         <em>",
"          Aspergillus",
"         </em>",
"         spp*",
"        </p>",
"        <p>",
"         <em>",
"          Sporothrix schenckii",
"         </em>",
"         *",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Parasites",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         <em>",
"          Taenia solium",
"         </em>",
"         (cysticercosis)*",
"        </p>",
"        <p>",
"         <em>",
"          Trichinella spiralis",
"         </em>",
"         *",
"        </p>",
"        <p>",
"         <em>",
"          Toxoplasma gondii",
"         </em>",
"         *",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Noninfectious causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Drugs",
"       </td>",
"       <td colspan=\"3\">",
"        <p>",
"         Ibuprofen",
"        </p>",
"        <p>",
"         Trimethoprim-sulfamethoxazole",
"        </p>",
"        <p>",
"         Other NSAIDS",
"        </p>",
"        <p>",
"         Pyridium (phenazopyridine)",
"        </p>",
"        <p>",
"         Anti-CD3 monoclonal antibody",
"        </p>",
"        <p>",
"         Azathioprine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Malignancy",
"       </td>",
"       <td colspan=\"3\">",
"        <p>",
"         Lymphoma*",
"        </p>",
"        <p>",
"         Leukemia*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Autoimmune",
"       </td>",
"       <td colspan=\"3\">",
"        <p>",
"         Sarcoid*",
"        </p>",
"        <p>",
"         Behcet's disease*",
"        </p>",
"        <p>",
"         Systemic lupus erythematosus*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Other causes",
"       </td>",
"       <td colspan=\"3\">",
"        <p>",
"         Epidermoid cyst*",
"        </p>",
"        <p>",
"         Postvaccination",
"        </p>",
"        <p>",
"         Heavy metal poisoning*",
"        </p>",
"        <p>",
"         Intracranial hemorrhage*",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Treatable cause.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sawyer MH, Rotbart HA. Aseptic and viral meningitis. In: Principles and Practice of Pediatric Infectious Diseases, 3rd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. Copyright &copy; 2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36237=[""].join("\n");
var outline_f35_24_36237=null;
var title_f35_24_36238="Blunt mobilization of the right colon";
var content_f35_24_36238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blunt mobilization of the right colon from retroperitoneal structures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates blunt dissction of the space between the peritoneum of the ascending colon and the underlying retroperitoneal structures (eg, kidney, ureter, godal vessels).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36238=[""].join("\n");
var outline_f35_24_36238=null;
var title_f35_24_36239="Bounce home test";
var content_f35_24_36239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55603&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The bounce home test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bounce home test is a test of knee extension. It is performed with the patient supine. The knee is passively flexed to approximately 15 degrees and then permitted to fall into extension with gravity. The test is positive if the knee does not fully extend.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_24_36239=[""].join("\n");
var outline_f35_24_36239=null;
